World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

References

• Abelson JL, Curtis GC, Sagher O, Albucher RC, Harrigan M, Taylor SF, et al. Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry 2005; 57: 510–516
   PubMed Web of Science ®Google Scholar
• Abramowitz JS. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J Consult Clin Psychol 1997; 65: 44–52
   PubMed Web of Science ®Google Scholar
• ACOG. 2006. ACOG Committee Opinion No. 354: Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 108:1601–1603.
   Google Scholar
• Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology. J Clin Psychiatry 1999; 60: 55–56
   PubMed Web of Science ®Google Scholar
• Agid O, Shalev AY, Lerer B. Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. J Clin Psychiatry 2001; 62: 169–173
   PubMed Web of Science ®Google Scholar
• Alamy S, Wei Z, Varia I, Davidson JR, Connor KM. Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol 2008; 22: 157–161
   PubMedGoogle Scholar
• Albert U, Aguglia E, Maina G, Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J Clin Psychiatry 2002; 63: 1004–1009
   PubMed Web of Science ®Google Scholar
• Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008; 23: 109–114
   PubMed Web of Science ®Google Scholar
• Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 1999; 100: 193–198
   PubMed Web of Science ®Google Scholar
• Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15–22
   PubMed Web of Science ®Google Scholar
• Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, et al. WCA-recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectrums 2003; 8: 53–61
   PubMed Web of Science ®Google Scholar
• Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 2004a; 161: 1642–1649
   PubMed Web of Science ®Google Scholar
• Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjodin I, et al. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004b; 19: 387–396
   PubMed Web of Science ®Google Scholar
• Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505
   PubMed Web of Science ®Google Scholar
• Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, et al. A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder. J Psychopharmacol 2008; 22: 417–425
   PubMed Web of Science ®Google Scholar
• Alonso P, Pujol J, Cardoner N, Benlloch L, Deus J, Menchon JM, et al. Right prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 1143–1145
   PubMed Web of Science ®Google Scholar
• Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999; 14: 239–245
   PubMed Web of Science ®Google Scholar
• Altshuler LL Cohen LS Moline ML Kahn DA Carpenter D Docherty JP 2001. The Expert Consensus Guideline Series. Treatment of depression in women Postgrad Med 1–107.
   PubMedGoogle Scholar
• Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New Engl J Med 2007; 356: 2684–2692
   PubMed Web of Science ®Google Scholar
• Amiaz R, Fostick L, Gershon A, Zohar J. Naltrexone augmentation in OCD: a double-blind placebo-controlled cross-over study. Eur Neuropsychopharmacol 2008; 18: 455–461
   PubMed Web of Science ®Google Scholar
• Amore M, Magnani K, Cerisoli M, Casagrande C, Ferrari G. Panic disorder. A long-term treatment study: Fluoxetine vs imipramine. Hum Psychopharmacol Clin Exp 1999a; 14: 429–434
   Web of Science ®Google Scholar
• Amore M, Magnani K, Cerisoli M, Ferrari G. Short-term and long-term evaluation of selective serotonin reuptake inhibitors in the treatment of panic disorder: fluoxetine vs citalopram. Hum Psychopharmacol Clin Exp 1999b; 14: 435–440
   Google Scholar
• Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 1991; 365: 18–27
   PubMedGoogle Scholar
• Anderson D, Ahmed A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation. Case report. J Neurosurg 2003; 98: 1104–1108
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Grigsby AB, Freedland KE, de Groot M, McGill JB, Clouse RE, et al. Anxiety and poor glycemic control: a meta-analytic review of the literature. Int J Psychiatry Med 2002; 32: 235–247
   PubMed Web of Science ®Google Scholar
• Andréewitch S Murphy TK Petralia A Mandel F Herman B. 2008. Efficacy of pregabalin and venlafaxine-XR in genrelized anxiety disorder: results from a double-blind, placebo-controlled 8-week trial. Poster, 16th AEP European Congress of Psychiatry, 5–9 April, Nice, France.
   Google Scholar
• Andrews G. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust NZ J Psychiatry 2003; 37: 641–656
   Google Scholar
• Ansseau M, Olie JP, von Frenckell R, Jourdain G, Stehle B, Guillet P. Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. Psychopharmacology 1991; 104: 439–443
   PubMed Web of Science ®Google Scholar
• Aouizerate B, Cuny E, Martin-Guehl C, Guehl D, Amieva H, Benazzouz A, et al. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J Neurosurg 2004; 101: 682–686
   PubMed Web of Science ®Google Scholar
• APA . 2000. Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision (DSM-IV-TR®). Washington, DC: American Psychiatric Press.
   Google Scholar
• Arntz A. Cognitive therapy versus applied relaxation as treatment of generalized anxiety disorder. Behav Res Ther 2003; 41: 633–646
   PubMed Web of Science ®Google Scholar
• Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2007; 10: 263–274
   PubMed Web of Science ®Google Scholar
• Asnis GM, Hameedi FA, Goddard AW, Potkin SG, Black D, Jameel M, et al. Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo–controlled study in outpatients. Psychiatry Res 2001; 103: 1–14
   PubMed Web of Science ®Google Scholar
• Atmaca M, Kuloglu M, Tezcan E, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study. Int Clin Psychopharmacol 2002; 17: 115–119
   PubMed Web of Science ®Google Scholar
• Austin MPV, Mitchell PB. Psychotropic medications in pregnant women: treatment dilemmas. Med J Australia 1998; 169: 428–431
   Google Scholar
• Baer L Rauch SL Ballantine HT, Jr Martuza R Cosgrove R, et al. 1995. Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 52:384–392.
   PubMed Web of Science ®Google Scholar
• Baer S, Garland EJ. Pilot study of community-based cognitive behavioral group therapy for adolescents with social phobia. J Am Acad Child Adolesc Psychiatry 2005; 44: 258–264
   PubMed Web of Science ®Google Scholar
• Bakish D, Hooper CL, Filteau MJ, Charbonneau Y, Fraser G, West DL, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996; 32: 135–141
   PubMed Web of Science ®Google Scholar
• Bakker A, van Dyck R, Spinhoven P, van Balkom A. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry 1999; 60: 831–838
   PubMed Web of Science ®Google Scholar
• Baldwin D, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 1999; 175: 120–126
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567–596
   PubMed Web of Science ®Google Scholar
• Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264–272
   PubMed Web of Science ®Google Scholar
• Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. J Clin Psychiatry 2005; 66: 94–99
   PubMed Web of Science ®Google Scholar
• Ballenger JC Burrows GD DuPont RL, Jr Lesser IM Noyes R, Jr Pecknold JC, et al. 1988. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment Arch Gen Psychiatry 45:413–422.
   PubMedGoogle Scholar
• Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998; 155: 36–42
   PubMed Web of Science ®Google Scholar
• Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Borkovec TD, Rickels K, et al. Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 2001; 62(Suppl 11)53–58
   PubMed Web of Science ®Google Scholar
• Bandelow B. Panic and Agoraphobia Scale (PAS). Hogrefe & Huber Publishers, Göttingen/Bern/Toronto/Seattle 1999
   Google Scholar
• Bandelow B. Epidemiology of depression and anxiety. Handbook on depression and anxiety, S Kasper, JA den Boer, AJM Sitsen. Marcel Dekker, New York, NY 2003; 49–68
   Google Scholar
• Bandelow B. Sertraline and exposure therapy in social phobia. Br J Psychiatry 2004; 184: 271
   Google Scholar
• Bandelow B. Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectrums 2006; 11: 21–28
   PubMed Web of Science ®Google Scholar
• Bandelow B, Rüther E. Treatment-resistant panic disorder. CNS Spectrums 2004; 9: 725–739
   PubMed Web of Science ®Google Scholar
• Bandelow B, Haug TT. Sertraline and exposure therapy in social phobia. Author's reply. Br J Psychiatry 2004; 184: 271–272
   Google Scholar
• Bandelow B, Sievert K, Röthemeyer M, Hajak G, Rüther E. What treatments do patients with panic disorder and agoraphobia get?. Eur Arch Clin Psychiatry Neurosci 1995; 245: 165–71
   Google Scholar
• Bandelow B, Broocks A, Pekrun G, George A, Meyer T, Pralle L, et al. The use of the Panic and Agoraphobia Scale (P & A) in a controlled clinical trial. Pharmacopsychiatry 2000; 33: 174–181
   PubMed Web of Science ®Google Scholar
• Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Dombrowski A, Goebel C. Sertraline versus paroxetine in the treatment of panic disorder: A multinational randomized double-blind 15 week study. Eur Neuropsychopharmacol 2002a; 12: S364–364
   Google Scholar
• Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders. World J Biol Psychiatry 2002b; 3: 171–199
   PubMedGoogle Scholar
• Bandelow B, Behnke K, Lenoir S, Hendriks GJ, Alkin T, Goebel C, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double–blind noninferiority comparison. J Clin Psychiatry 2004; 65: 405–413
   PubMed Web of Science ®Google Scholar
• Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?. J Clin Psychiatry 2006; 67: 1428–1434
   PubMed Web of Science ®Google Scholar
• Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Rüther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry 2007a; 8: 175–87
   PubMed Web of Science ®Google Scholar
• Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 2007b; 40: 152–156
   PubMed Web of Science ®Google Scholar
• Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007c; 7: 769–781
   PubMedGoogle Scholar
• Bandelow B Chouinard G Bobes J Ahokas A Eggens I Liu S, et al. in preparation. Once-daily extended release quetiapine fumarate (quetiapine xr) monotherapy in generalized anxiety disorder: a phase III, randomized, double-blind, placebo-and active (paroxetine)-controlled study.
   Google Scholar
• Bankier B, Januzzi JL, Littman AB. The high prevalence of multiple psychiatric disorders in stable outpatients with coronary heart disease. Psychosom Med 2004; 66: 645–650
   PubMed Web of Science ®Google Scholar
• Barlow DH. Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 1997; 58: 32–37
   PubMed Web of Science ®Google Scholar
• Barlow D, Craske M, Cerny J, Klosko J. Behavioral treatment of panic disorder. Behav Ther 1989; 20: 261–282
   Web of Science ®Google Scholar
• Barlow DH, Rapee RM, Brown TA. Behavioral treatment of generalized anxiety disorder. Behav Ther 1992; 23: 551–570
   Web of Science ®Google Scholar
• Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. J Am Med Assoc 2000; 283: 2529–2536
   PubMed Web of Science ®Google Scholar
• Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002; 16: 365–368
   PubMed Web of Science ®Google Scholar
• Battista MA, Hierholzer R, Khouzam HR, Barlow A, O'Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry 2007; 70: 167–174
   PubMed Web of Science ®Google Scholar
• Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994; 14: 111–118
   PubMedGoogle Scholar
• Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry 1992; 149: 778–783
   PubMed Web of Science ®Google Scholar
• Becker ME, Hertzberg MA, Moore SD, Dennis MF, Bukenya DS, Beckham JC. A placebo-controlled trial of bupropion SR in the treatment of chronic posttraumatic stress disorder. J Clin Psychopharmacol 2007; 27: 193–197
   PubMed Web of Science ®Google Scholar
• Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995; 152: 1084–1086
   PubMed Web of Science ®Google Scholar
• Benjamin J, Ben-Zion IZ, Karbofsky E, Dannon P. Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology (Berlin) 2000; 149: 194–196
   PubMed Web of Science ®Google Scholar
• Berlant JL. Topiramate in posttraumatic stress disorder: Preliminary clinical observations. J Clin Psychiatry 2001; 62: 60–63
   PubMed Web of Science ®Google Scholar
• Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 2002; 63: 15–20
   PubMed Web of Science ®Google Scholar
• Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2004; 37: 206–210
   PubMed Web of Science ®Google Scholar
• Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005; 17: 65–69
   PubMedGoogle Scholar
• Birmaher B, Axelson DA, Monk K, Kalas C, Clark DB, Ehmann M, et al. Fluoxetine for the treatment of childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry 2003; 42: 415–423
   PubMed Web of Science ®Google Scholar
• Bisserbe J, Lane R, Flament M. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997; 12: 82–93
   PubMed Web of Science ®Google Scholar
• Bisson JI, Jenkins PL, Alexander J, Bannister C. Randomised controlled trial of psychological debriefing for victims of acute burn trauma. Br J Psychiatry 1997; 171: 78–81
   PubMed Web of Science ®Google Scholar
• Black DW, Wesner R, Bowers W, Gabel J. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993; 50: 44–50
   PubMed Web of Science ®Google Scholar
• Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, et al. The development of a clinician-administered PTSD Scale. J Trauma Stress 1995; 8: 75–90
   PubMed Web of Science ®Google Scholar
• Blanchard EB, Hickling EJ, Devineni T, Veazey CH, Galovski TE, Mundy E, et al. A controlled evaluation of cognitive behavioural therapy for posttraumatic stress in motor vehicle accident survivors. Behav Res Ther 2003; 41: 79–96
   PubMed Web of Science ®Google Scholar
• Blaya C, Seganfredo AC, Dornelles M, Torres M, Paludo A, Heldt E, et al. The efficacy of milnacipran in panic disorder: an open trial. Int Clin Psychopharmacol 2007; 22: 153–158
   PubMed Web of Science ®Google Scholar
• Blier P, Bergeron R. Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: preliminary findings. Int Clin Psychopharmacol 1996; 11: 37–44
   Google Scholar
• Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622–632
   PubMed Web of Science ®Google Scholar
• Blomhoff S, Tangen Haug T, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179: 23–30
   PubMed Web of Science ®Google Scholar
• Bogan AM, Koran LM, Chuong HW, Vapnik T, Bystritsky A. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study. J Clin Psychiatry 2005; 66: 73–79
   PubMed Web of Science ®Google Scholar
• Bogetto F, Bellino S, Vaschetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res 2000; 96: 91–98
   PubMed Web of Science ®Google Scholar
• Bolton D, Perrin S. Evaluation of exposure with response-prevention for obsessive compulsive disorder in childhood and adolescence. J Behav Ther Exp Psychiatry 2008; 39: 11–22
   PubMed Web of Science ®Google Scholar
• Bonne O, Shemer Y, Gorali Y, Katz M, Shalev AY. A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. J Clin Psychiatry 2003; 64: 282–287
   PubMedGoogle Scholar
• Book SW, Thomas SE, Randall PK, Randall CL. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. J Anxiety Disord 2008; 22: 310–318
   PubMed Web of Science ®Google Scholar
• Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1993; 61: 611–619
   PubMed Web of Science ®Google Scholar
• Borkovec TD, Mathews AM, Chambers A, Ebrahimi S, Lytle R, Nelson R. The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety. J Consult Clin Psychol 1987; 55: 883–888
   PubMed Web of Science ®Google Scholar
• Bose A Korotzer A Gommoll C Li D. 2007. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. Epub date: 2007/12/01.
   Google Scholar
• Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998; 49: 79–82
   PubMed Web of Science ®Google Scholar
• Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 1995; 10: 45–49
   PubMed Web of Science ®Google Scholar
• Boyer WF, Feighner JP. A placebo-controlled double-blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. Int Clin Psychopharmacol 1993; 8: 173–176
   PubMed Web of Science ®Google Scholar
• Bradwejn J. Benzodiazepines for the treatment of panic disorder and generalized anxiety disorder: clinical issues and future directions. Can J Psychiatry 1993; 38(Suppl 4)S109–113
   Google Scholar
• Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005; 187: 352–359
   PubMed Web of Science ®Google Scholar
• Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. J Am Med Assoc 2000; 283: 1837–1844
   PubMed Web of Science ®Google Scholar
• Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatr Q 1993; 64: 135–149
   PubMedGoogle Scholar
• Braun P, Greenberg D, Dasberg H, Lerer B. Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 1990; 51: 236–238
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: a double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321–1325
   PubMed Web of Science ®Google Scholar
• Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2006; 67: 874–881
   PubMed Web of Science ®Google Scholar
• Bremner DJ, Mletzko T, Welter S, Siddiq S, Reed L, Williams C, et al. Treatment of posttraumatic stress disorder with phenytoin: an open-label pilot study. J Clin Psychiatry 2004; 65: 1559–1564
   Google Scholar
• Brenes GA. Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003; 65: 963–970
   PubMed Web of Science ®Google Scholar
• Bryant RA, Moulds ML, Guthrie RM, Dang ST, Nixon RD. Imaginal exposure alone and imaginal exposure with cognitive restructuring in treatment of posttraumatic stress disorder. J Consult Clin Psychol 2003; 71: 706–712
   PubMed Web of Science ®Google Scholar
• Bunevicius R Prange AJ, Jr 2006. Psychiatric manifestations of Graves' hyperthyroidism: pathophysiology and treatment options. CNS Drugs 20:897–909.
   PubMed Web of Science ®Google Scholar
• Butler G, Fennell M, Robson P, Gelder M. Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol 1991; 59: 167–175
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Rosen RM, Murphy KJ, Bohn P, Keys SA, Vapnik T. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994; 1: 287–290
   PubMedGoogle Scholar
• Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, et al. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 2004; 65: 565–568
   PubMed Web of Science ®Google Scholar
• Bystritsky A, Kerwin L, Feusner JD, Vapnik T. A pilot controlled trial of bupropion xl versus escitalopram in generalized anxiety disorder. Psychopharmacol Bull 2008; 41: 46–51
   PubMedGoogle Scholar
• Canadian Psychiatric Association. 2006. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 51:9S–91S.
   PubMedGoogle Scholar
• Carey PD, Vythilingum B, Seedat S, Muller JE, van Ameringen M, Stein DJ. Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762]. BMC Psychiatry 2005; 5: 5
   PubMed Web of Science ®Google Scholar
• Carlbring P, Bohman S, Brunt S, Buhrman M, Westling BE, Ekselius L, et al. Remote treatment of panic disorder: a randomized trial of internet-based cognitive behavior therapy supplemented with telephone calls. Am J Psychiatry 2006; 163: 2119–2125
   PubMed Web of Science ®Google Scholar
• Carlson J, Chemtob CM, Rusnak K, Hedlund NL, Muraoka MY. Eye movement desensitization and reprocessing (EMDR): Treatment for combat-related post-traumatic stress disorder. J Traumatic Stress 1998; 11: 3–24
   PubMed Web of Science ®Google Scholar
• Carpenter LL, Leon Z, Yasmin S, Price LH. Clinical experience with mirtazapine in the treatment of panic disorder. Ann Clin Psychiatry 1999; 11: 81–86
   PubMedGoogle Scholar
• Casas M, Alvarez E, Duro P, Garcia-Ribera C, Udina C, Velat A, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986; 73: 221–222
   PubMed Web of Science ®Google Scholar
• Cassano GB, Petracca A, Perugi G, Nisita C, Musetti L, Mengali F, et al. Clomipramine for panic disorder: I. The first 10 weeks of a long-term comparison with imipramine. J Affect Disord 1988; 14: 123–127
   Google Scholar
• Cavaljuga S, Licanin I, Kapic E, Potkonjak D. Clomipramine and fluoxetine effects in the treatment of panic disorder. Bosn J Basic Med Sci 2003; 3: 27–31
   PubMedGoogle Scholar
• Chao IL. Olanzapine augmentation in panic disorder: a case report. Pharmacopsychiatry 2004; 37: 239–240
   Google Scholar
• Charney D, Bremner D. The neurobiology of anxiety disorders. Neurobiology of mental illness, D Charney. Oxford Press, Oxford 1999; 494–517
   Google Scholar
• Charney DS, Woods SW. Benzodiazepine treatment of panic disorder: a comparison of alprazolam and lorazepam. J Clin Psychiatry 1989; 50: 418–423
   PubMed Web of Science ®Google Scholar
• Charney DS, Woods SW, Goodman WK, Rifkin B, Kinch M, Aiken B, et al. Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 1986; 47: 580–586
   PubMed Web of Science ®Google Scholar
• Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, et al. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol Bull 1990; 26: 279–284
   PubMedGoogle Scholar
• Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry 1994; 164: 759–769
   PubMed Web of Science ®Google Scholar
• Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71: 1058–1067
   PubMed Web of Science ®Google Scholar
• Clark DM, Ehlers A, Hackmann A, McManus F, Fennell M, Grey N, et al. Cognitive therapy versus exposure and applied relaxation in social phobia: A randomized controlled trial. J Consult Clin Psychol 2006; 74: 568–578
   PubMed Web of Science ®Google Scholar
• Cloitre M, Koenen KC, Cohen LR, Han H. Skills training in affective and interpersonal regulation followed by exposure: A phase-based treatment for PTSD related to childhood abuse. J Consult Clin Psychology 2002; 70: 1067–1074
   PubMed Web of Science ®Google Scholar
• Clomipramine Collaborative Study Group. 1991. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group. Arch Gen Psychiatry 48:730–738.
   PubMed Web of Science ®Google Scholar
• Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993; 61: 317–326
   PubMed Web of Science ®Google Scholar
• CNCPS. 1992. Cross-national collaborative panic study. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiat 160:191–202.
   PubMed Web of Science ®Google Scholar
• Cohen H, Kaplan Z, Kotler M, Kouperman I, Moisa R, Grisaru N. Repetitive transcranial magnetic stimulation of the right dorsolateral prefrontal cortex in posttraumatic stress disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2004; 161: 515–524
   PubMed Web of Science ®Google Scholar
• Cohen SD, Monteiro W, Marks IM. Two-year follow-up of agoraphobics after exposure and imipramine. Br J Psychiatry 1984; 144: 276–281
   PubMed Web of Science ®Google Scholar
• Conlon L, Fahy TJ, Conroy R. PTSD in ambulant RTA victims: a randomized controlled trial of debriefing. J Psychosom Res 1999; 46: 37–44
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR. Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives. Biol Psychiatry 1998; 44: 1286–1294
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson J. A placebo-controlled study of Kava kava in generalized anxiety disorder. Int Clin Psychopharmacol 2002; 17: 185–188
   PubMed Web of Science ®Google Scholar
• Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry 1999; 175: 17–22
   PubMed Web of Science ®Google Scholar
• Connor KM, Payne VM, Gadde KM, Zhang W, Davidson JR. The use of aripiprazole in obsessive-compulsive disorder: preliminary observations in 8 patients. J Clin Psychiatry 2005; 66: 49–51
   PubMed Web of Science ®Google Scholar
• Connor KM, Davidson JR, Weisler RH, Zhang W, Abraham K. Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (Berlin) 2006a; 184: 21–25
   PubMed Web of Science ®Google Scholar
• Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. Int Clin Psychopharmacol 2006b; 21: 249–253
   Google Scholar
• Cordioli AV, Heldt E, Bochi DB. Cognitive-behavioral group therapy in obsessive-compulsive disorder: A randomized clinical trial. Psychother Psychosom 2003; 72: 211–216
   PubMed Web of Science ®Google Scholar
• Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 2005; 58: 424–428
   PubMed Web of Science ®Google Scholar
• Cottraux J, Mollard E, Bouvard M, Marks I, Sluys M, Nury AM, et al. A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 1990; 5: 17–30
   PubMed Web of Science ®Google Scholar
• Cottraux J, Mollard E, Bouvard M, Marks I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res 1993; 49: 63–75
   PubMed Web of Science ®Google Scholar
• Cottraux J, Note ID, Cungi C, Legeron P, Heim F, Chneiweiss L, et al. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia. Br J Psychiatry 1995; 167: 635–641
   PubMedGoogle Scholar
• Cottraux J, Note I, Albuisson E, Yao SN, Note B, Mollard E, et al. Cognitive behavior therapy versus supportive therapy in social phobia: a randomized controlled trial. Psychother Psychosom 2000; 69: 137–146
   PubMed Web of Science ®Google Scholar
• Cottraux J, Bouvard MA, Milliery M. Combining Pharmacotherapy with cognitive-behavioral interventions for obsessive-compulsive disorder. Cogn Behav Ther 2005; 34: 185–192
   PubMedGoogle Scholar
• Cournoyer J. Reponse rapide a l'addition du carbonate de lithium d'un trouble: panique resistant aux antidepresseurs tricycliques [Rapid response of a disorder to the addition of lithium carbonate: panic resistant to tricyclic antidepressants]. Can J Psychiatry 1986; 31: 335–338
   Google Scholar
• Cowley DS, Ha EH, Roy-Byrne PP. Determinants of pharmacologic treatment failure in panic disorder. J Clin Psychiatry 1997; 58: 555–561
   PubMed Web of Science ®Google Scholar
• Cox B, Swinson R, Lee P. Meta-analysis of anxiety disorder treatment studies. J Clin Psychopharmacol 1992a; 12: 300–301
   Google Scholar
• Cox BJ, Endler NS, Lee PS, Swinson RP. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry 1992b; 23: 175–182
   PubMedGoogle Scholar
• Crockett BA, Churchill E, Davidson JR. A double-blind combination study of clonazepam with sertraline in obsessive-compulsive disorder. Ann Clin Psychiatry 2004; 16: 127–132
   PubMedGoogle Scholar
• Cumming S, Hay P, Lee T, Sachdev P. Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder. Aust NZ J Psychiatry 1995; 29: 293–298
   PubMed Web of Science ®Google Scholar
• Curtis GC, Massana J, Udina C, Ayuso JL, Cassano GB, Perugi G. Maintenance drug therapy of panic disorder. J Psychiatr Res 1993; 27(Suppl 1)127–142
   Google Scholar
• da Rocha FF, Correa H. Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1550–1551
   Google Scholar
• Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur Neuropsychopharmacol 2000; 10: 165–169
   PubMed Web of Science ®Google Scholar
• Dannon PN, Gon-Usishkin M, Gelbert A, Lowengrub K, Grunhaus L. Cognitive behavioral group therapy in panic disorder patients: the efficacy of CBGT versus drug treatment. Ann Clin Psychiatry 2004; 16: 41–46
   PubMedGoogle Scholar
• Davidson J, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47: 259–266
   PubMed Web of Science ®Google Scholar
• Davidson J, Pearlstein T, Londborg P, Brady KT, Rothbaum B, Bell J, et al. Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 2001a; 158: 1974–1981
   PubMed Web of Science ®Google Scholar
• Davidson J, Yaryura-Tobias J, DuPont R, Stallings L, Barbato LM, van der Hoop RG, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004a; 24: 118–125
   PubMed Web of Science ®Google Scholar
• Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006a; 63: 1158–1165
   PubMed Web of Science ®Google Scholar
• Davidson J, Rothbaum BO, Tucker P, Asnis G, Benattia I, Musgnung JJ. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006b; 26: 259–267
   PubMed Web of Science ®Google Scholar
• Davidson JR, Kudler HS, Saunders WB, Erickson L, Smith RD, Stein RM. Predicting response to amitriptyline in posttraumatic stress disorder. Am J Psychiatry 1993a; 150: 1024–1029
   PubMed Web of Science ®Google Scholar
• Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993b; 13: 423–428
   PubMed Web of Science ®Google Scholar
• Davidson JR, Weisler RH, Malik M, Tupler LA. Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol 1998; 18: 93–95
   Google Scholar
• Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999; 60: 528–535
   PubMed Web of Science ®Google Scholar
• Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001b; 58: 485–492
   PubMed Web of Science ®Google Scholar
• Davidson JR, Weisler RH, Butterfield MI, Casat CD, Connor KM, Barnett S, et al. Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 2003; 53: 188–191
   PubMed Web of Science ®Google Scholar
• Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004b; 19: 234–240
   PubMed Web of Science ®Google Scholar
• Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiatry 2004c; 61: 1005–1013
   PubMed Web of Science ®Google Scholar
• Davidson JR, Connor KM, Hertzberg MA, Weisler RH, Wilson WH, Payne VM. Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol 2005; 25: 166–169
   PubMed Web of Science ®Google Scholar
• Davidson JR, Brady K, Mellman TA, Stein MB, Pollack MH. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 2007a; 27: 85–88
   PubMed Web of Science ®Google Scholar
• Davidson JRT Wittchen HU Llorca PM Erickson J Detke M Ball SG, et al. 2007b. Duloxetine 60 to 120 mg once daily for the prevention of relapse in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Poster, ACNP, Boca Raton, 9–13 December.
   Google Scholar
• Davies SJ, Jackson PR, Potokar J, Nutt DJ. Treatment of anxiety and depressive disorders in patients with cardiovascular disease. Br Med J 2004; 328: 939–943
   PubMedGoogle Scholar
• Davis LL, Davidson JR, Ward LC, Bartolucci A, Bowden CL, Petty F. Divalproex in the treatment of posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial in a veteran population. J Clin Psychopharmacol 2008a; 28: 84–88
   PubMed Web of Science ®Google Scholar
• Davis LL, Ward C, Rasmusson A, Newell JM, Frazier E, Southwick SM. A placebo-controlled trial of guanfacine for the treatment of posttraumatic stress disorder in veterans. Psychopharmacol Bull 2008b; 41: 8–18
   PubMed Web of Science ®Google Scholar
• de Beurs E, van Balkom AJ, Lange A, Koele P, van Dyck R. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995; 152: 683–691
   PubMed Web of Science ®Google Scholar
• Deahl M, Srinivasan M, Jones N, Thomas J, Neblett C, Jolly A. Preventing psychological trauma in soldiers: the role of operational stress training and psychological debriefing. Br J Med Psychol 2000; 73(Pt1)77–85
   Google Scholar
• Dell'Osso B, Mundo E, Altamura AC. Quetiapine augmentation of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a six-month follow-up case series. CNS Spectrums 2006; 11: 879–883
   PubMed Web of Science ®Google Scholar
• Dell'osso B, Mundo E, Marazziti D, Altamura AC. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J Psychopharmacol 2008; 22: 210–213
   PubMed Web of Science ®Google Scholar
• den Boer JA, Westenberg HG. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988; 3: 59–74
   PubMed Web of Science ®Google Scholar
• den Boer JA, Westenberg HG. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berlin) 1990; 102: 85–94
   PubMed Web of Science ®Google Scholar
• Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003; 23: 568–575
   PubMed Web of Science ®Google Scholar
• Denys D, De Geus F, Van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 2004a; 65: 1040–1048
   PubMed Web of Science ®Google Scholar
• Denys D, van Megen HJ, van der Wee N, Westenberg HG. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004b; 65: 37–43
   PubMed Web of Science ®Google Scholar
• DeVane CL, Ware MR, Emmanuel NP, Brawman-Mintzer O, Morton WA, Villarreal G, et al. Evaluation of the efficacy, safety and physiological effects of fluvoxamine in social phobia. Int Clin Psychopharmacol 1999; 14: 345–351
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989; 25: 36–40
   PubMedGoogle Scholar
• DeVeaugh-Geiss J, Moroz G, Biederman J, Cantwell D, Fontaine R, Greist JH, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder – a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31: 45–49
   PubMed Web of Science ®Google Scholar
• Devilly GJ, Spence SH. The relative efficacy and treatment distress of EMDR and a cognitive-behavior trauma treatment protocol in the amelioration of posttraumatic stress disorder. J Anxiety Disord 1999; 13: 131–157
   PubMed Web of Science ®Google Scholar
• Dieleman GC, Ferdinand RF. Pharmacotherapy for social phobia, generalised anxiety disorder and separation anxiety disorder in children and adolescents: an overview. Tijdschr Psychiatr 2008; 50: 43–53
   PubMedGoogle Scholar
• Dieperink ME, Drogemuller L. Zolpidem for insomnia related to PTSD. Psychiatr Serv 1999; 50: 421
   PubMed Web of Science ®Google Scholar
• Dougherty DD, Baer L, Cosgrove GR, Cassem EH, Price BH, Nierenberg AA, et al. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am J Psychiatry 2002; 159: 269–275
   PubMed Web of Science ®Google Scholar
• Dugas MJ, Ladouceur R, Leger E, Freeston MH, Langlois F, Provencher MD, et al. Group cognitive-behavioral therapy for generalized anxiety disorder: treatment outcome and long-term follow-up. J Consult Clin Psychol 2003; 71: 821–825
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Papp L, Garlow SJ, Weiss PS, Knight BT, Ninan PT. Tiagabine for social anxiety disorder. Hum Psychopharmacol 2007; 22: 241–244
   PubMed Web of Science ®Google Scholar
• Dunner DL, Ishiki D, Avery DH, Wilson LG, Hyde TS. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study. J Clin Psychiatry 1986; 47: 458–460
   PubMed Web of Science ®Google Scholar
• DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. Economic costs of anxiety disorders. Anxiety 1996; 2: 167–172
   PubMedGoogle Scholar
• Durham RC, Murphy T, Allan T, Richard K, Treliving LR, Fenton GW. Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. Br J Psychiatry 1994; 165: 315–23
   PubMed Web of Science ®Google Scholar
• Dyukova GM, Shepeleva IP, Vorob'eva OV. Treatment of negative crises (panic attacks). Neurosci Behav Physiol 1992; 22: 343–345
   Google Scholar
• Eccles M, Mason J. How to develop cost-conscious guidelines. Health Technol Assess 2001; 5: 1–69
   PubMedGoogle Scholar
• Echeburua E, de Corral P, Zubizarreta I, Sarasua B. Psychological treatment of chronic posttraumatic stress disorder in victims of sexual aggression. Behav Modif 1997; 21: 433–456
   PubMed Web of Science ®Google Scholar
• Elie R, Lamontagne Y. Alprazolam and diazepam in the treatment of generalized anxiety. J Clin Psychopharmacol 1984; 4: 125–129
   PubMed Web of Science ®Google Scholar
• Emslie G, Judge R. Tricyclic antidepressants and selective serotonin reuptake inhibitors: use during pregnancy, in children/adolescents and in the elderly. Acta Psychiatr Scand 2000; 101: 26–34
   Google Scholar
• Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology 1991; 105: 428–432
   PubMed Web of Science ®Google Scholar
• Ericson A, Kallen B, Wiholm BE. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999; 55: 503–508
   PubMed Web of Science ®Google Scholar
• Eriksson T. Anti-androgenic treatment of obsessive-compulsive disorder: an open-label clinical trial of the long-acting gonadotropin-releasing hormone analogue triptorelin. Int Clin Psychopharmacol 2007; 22: 57–61
   Google Scholar
• Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. Eur Neuropsychopharmacol 2005; 15: 69–74
   PubMed Web of Science ®Google Scholar
• Escalona R, Canive JM, Calais LA, Davidson JR. Fluvoxamine treatment in veterans with combat-related post-traumatic stress disorder. Depress Anxiety 2002; 15: 29–33
   PubMed Web of Science ®Google Scholar
• Etxebeste M, Aragüés E, Malo P, Pacheco L. Olanzapine and panic attacks. Am J Psychiatry 2000; 157: 659–60
   PubMed Web of Science ®Google Scholar
• Fahy TJ, O'Rourke D, Brophy J, Schazmann W, Sciascia S. The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. J Affect Disord 1992; 25: 63–75
   Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132–191
   PubMed Web of Science ®Google Scholar
• Fallon BA, Liebowitz MR, Campeas R, Schneier FR, Marshall R, Davies S, et al. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: a placebo-controlled study. Arch Gen Psychiatry 1998; 55: 918–924
   PubMed Web of Science ®Google Scholar
• Famularo R, Kinscherff R, Fenton T. Propranolol treatment for childhood posttraumatic stress disorder, acute type. A pilot study. Am J Dis Child 1988; 142: 1244–1247
   PubMedGoogle Scholar
• Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001; 21: 311–324
   PubMed Web of Science ®Google Scholar
• Feighner JP. Buspirone in the long-term treatment of generalized anxiety disorder. J Clin Psychiatry (Suppl) 1987; 48: 3–6
   PubMed Web of Science ®Google Scholar
• Feighner JP, Merideth CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982; 43: 103–108
   PubMed Web of Science ®Google Scholar
• Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18–28
   PubMed Web of Science ®Google Scholar
• Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, et al. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23: 240–249
   PubMed Web of Science ®Google Scholar
• Ferguson JM, Khan A, Mangano R, Entsuah R, Tzanis E. Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 2007; 68: 58–68
   PubMed Web of Science ®Google Scholar
• Ferreri M, Hantouche EG, Billardon M. Interêt de l'hydroxyzine dans le trouble anxiété géneralisée: étude contrôle en double aveugle versus placebo. Encéphale 1994; 20: 785–791
   PubMedGoogle Scholar
• Feske U, Goldstein AJ. Eye movement desensitization and reprocessing treatment for panic disorder: a controlled outcome and partial dismantling study. J Consult Clin Psychol 1997; 65: 1026–1035
   PubMed Web of Science ®Google Scholar
• Fesler FA. Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 1991; 52: 361–364
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 2005; 20: 223–226
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, et al. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006; 21: 337–343
   PubMed Web of Science ®Google Scholar
• Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 2007; 17: 430–439
   PubMed Web of Science ®Google Scholar
• Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9: 115–123
   PubMed Web of Science ®Google Scholar
• Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, et al. Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 1985; 42: 977–983
   PubMed Web of Science ®Google Scholar
• Foa EB. Psychosocial treatment of posttraumatic stress disorder. J Clin Psychiatry 2000; 61(Suppl 5)43–48
   PubMed Web of Science ®Google Scholar
• Foa EB, Rothbaum BO, Riggs DS, Murdock TB. Treatment of posttraumatic stress disorder in rape victims: a comparison between cognitive-behavioral procedures and counseling. J Consult Clin Psychol 1991; 59: 715–723
   PubMed Web of Science ®Google Scholar
• Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP. A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol 1999; 67: 194–200
   PubMed Web of Science ®Google Scholar
• Foa EB, Liebowitz MR, Kozak MJ, Davies S, Campeas R, Franklin ME, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 151–161
   PubMed Web of Science ®Google Scholar
• Fontaine R, Annable L, Chouinard G, Ogilvie RI. Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol 1983; 3: 80–87
   PubMedGoogle Scholar
• Fontenelle LF, Mendlowicz MV, Miguel EC, Versiani M. Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder. World J Biol Psychiatry 2005; 6: 57–59
   PubMed Web of Science ®Google Scholar
• Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study. Can J Psychiatry 2001; 46: 356–358
   PubMed Web of Science ®Google Scholar
• Frank JB Kosten TR Giller EL, Jr Dan E. 1988. A randomized clinical trial of phenelzine and imipramine for posttraumatic stress disorder. Am J Psychiatry 145:1289–1291.
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lesperance F. Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008; 65: 62–71
   PubMed Web of Science ®Google Scholar
• Freeston MH, Ladouceur R, Gagnon F, Thibodeau N, Rheaume J, Letarte H, et al. Cognitive-behavioral treatment of obsessive thoughts: a controlled study. J Consult Clin Psychol 1997; 65: 405–413
   PubMed Web of Science ®Google Scholar
• Friedman MJ, Marmar CR, Baker DG, Sikes CR, Farfel GM. Randomized, double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 2007a; 68: 711–720
   PubMed Web of Science ®Google Scholar
• Friedman S, Abdallah TA, Oumaya M, Rouillon F, Guelfi JD. Aripiprazole augmentation of clomipramine-refractory obsessive-compulsive disorder. J Clin Psychiatry 2007b; 68: 972–973
   PubMedGoogle Scholar
• Frommberger U. Acute and chronic posttraumatic stress disorder. Fortschr Neurol Psychiatr 2004; 72: 411–421
   Google Scholar
• Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 2005; 58: 132–142
   PubMed Web of Science ®Google Scholar
• Furukawa TA Streiner DL Young LT 2002. Antidepressant and benzodiazepine for major depression (Cochrane Review). Cochrane Database Syst Rev CD001026.
   Google Scholar
• Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 2006; 188: 305–312
   PubMed Web of Science ®Google Scholar
• Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 1996; 153: 1219–1221
   PubMed Web of Science ®Google Scholar
• Fux M, Benjamin J, Belmaker RH. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int J Neuropsychopharmcol 1999; 2: 193–195
   PubMed Web of Science ®Google Scholar
• Gabriels L, Cosyns P, Nuttin B, Demeulemeester H, Gybels J. Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatr Scand 2003; 107: 275–282
   PubMed Web of Science ®Google Scholar
• Gade K Häußinger C Bandelow B submitted. Anorexia due to obsessive-compulsive disorder in a male patient successfully treated with naltrexone.
   Google Scholar
• Galvao-de Almeida A, Quarantini LC, Gois CR, Santos-Jesus R, Miranda-Scippa AM, de Oliveira IR, et al. Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. CNS Spectrums 2007; 12: 519–524
   PubMedGoogle Scholar
• Garattini S, Bertele V. Non-inferiority trials are unethical because they disregard patients' interests. Lancet 2007; 370: 1875–1877
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. J Am Med Assoc 2000; 283: 3082–3088
   PubMed Web of Science ®Google Scholar
• Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 773–779
   PubMed Web of Science ®Google Scholar
• Geller DA, Biederman J, Stewart SE, Mullin B, Farrell C, Wagner KD, et al. Impact of comorbidity on treatment response to paroxetine in pediatric obsessive-compulsive disorder: is the use of exclusion criteria empirically supported in randomized clinical trials?. J Child Adolesc Psychopharmacol 2003; 13(Suppl 1)S19–29
   Google Scholar
• Geller DA, Wagner KD, Emslie G, Murphy T, Carpenter DJ, Wetherhold E, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43: 1387–1396
   PubMed Web of Science ®Google Scholar
• Gelpin E, Bonne O, Peri T, Brandes D, Shalev AY. Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 1996; 57: 390–394
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007; 164: 1356–1363
   PubMed Web of Science ®Google Scholar
• Gladsjo JA, Rapaport MH, McKinney R, Auerbach M, Hahn T, Rabin A, et al. Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. J Clin Psychopharmacol 2001; 21: 131–138
   Google Scholar
• Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001; 58: 681–686
   PubMed Web of Science ®Google Scholar
• Goldstein AJ, de Beurs E, Chambless DL, Wilson KA. EMDR for panic disorder with agoraphobia: comparison with waiting list and credible attention-placebo control conditions. J Consult Clin Psychol 2000; 68: 947–956
   Google Scholar
• Goldstein DJ, Sundell K. A review of the safety of selective serotonin reuptake inhibitors during pregnancy. Hum Psychopharmacol Clin Exp 1999; 14: 319–324
   Web of Science ®Google Scholar
• Goodman W, Rasmussen S, Price L, Mazure L, Henninger G, Charney D. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Arch Gen Psychiatry 1989a; 46: 1006–1011
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmussen SA, Delgado PL, Heninger GR, Charney DS. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 1989b; 46: 36–44
   PubMed Web of Science ®Google Scholar
• Goodman WK, Kozak MJ, Liebowitz M, White KL. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996; 11: 21–29
   PubMed Web of Science ®Google Scholar
• Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005; 87: 161–167
   PubMed Web of Science ®Google Scholar
• Gorman JM, Liebowitz MR, Fyer AJ, Goetz D, Campeas RB, Fyer MR, et al. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol 1987; 7: 329–332
   PubMed Web of Science ®Google Scholar
• Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000; 157: 493–505
   PubMed Web of Science ®Google Scholar
• Gould RA, Clum GA. Self-help plus minimal therapist contact in the treatment of panic disorder: a replication and extension. Behav Ther 1995; 26: 533–46
   Web of Science ®Google Scholar
• Gould RA, Clum GA, Shapiro D. The use of bibliotherapy in the treatment of panic: a preliminary investigation. Behav Ther 1993; 24: 241–252
   Web of Science ®Google Scholar
• Gould RA, Buckminster S, Pollack MH, Otto MW, Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis. Clin Psychol Sci Pract 1997; 4: 291–306
   Web of Science ®Google Scholar
• Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17: 761–767
   PubMed Web of Science ®Google Scholar
• Greenberg BD, George MS, Martin JD, Benjamin J, Schlaepfer TE, Altemus M, et al. Effect of prefrontal repetitive transcranial magnetic stimulation in obsessive-compulsive disorder: a preliminary study. Am J Psychiatry 1997; 154: 867–869
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Malone DA, Friehs GM, Rezai AR, Kubu CS, Malloy PF, et al. Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31: 2384–2393
   PubMed Web of Science ®Google Scholar
• Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995a; 52: 289–295
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW, Kobak KA, Chouinard G, DuBoff E, Halaris A, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995b; 10: 57–65
   PubMed Web of Science ®Google Scholar
• Greist JH, Jefferson JW, Kobak KA, Katzelnick DJ, Serlin RC. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995c; 52: 53–60
   PubMed Web of Science ®Google Scholar
• Greist JH, Marks IM, Baer L, Kobak KA, Wenzel KW, Hirsch MJ, et al. Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control. J Clin Psychiatry 2002; 63: 138–145
   PubMed Web of Science ®Google Scholar
• Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, et al. WCA recommendations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums 2003; 8: 7–16
   PubMed Web of Science ®Google Scholar
• Gruber RP. ECT for obsessive-compulsive symptoms (possible mechanisms of action). Dis Nerv Syst 1971; 32: 180–182
   PubMedGoogle Scholar
• Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63: 544–549
   PubMed Web of Science ®Google Scholar
• Haby MM, Donnelly M, Corry J, Vos T. Cognitive behavioural therapy for depression, panic disorder and generalized anxiety disorder: a meta-regression of factors that may predict outcome. Aust NZ J Psychiatry 2006; 40: 9–19
   PubMed Web of Science ®Google Scholar
• Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry 2003; 18: 182–187
   PubMed Web of Science ®Google Scholar
• Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50–55
   PubMed Web of Science ®Google Scholar
• Hamner MB, Frueh BC. Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post–traumatic stress disorder. Int Clin Psychopharmacol 1998; 13: 233–234
   PubMedGoogle Scholar
• Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry 2001; 13: 141–146
   PubMedGoogle Scholar
• Hamner MB, Deitsch SE, Brodrick PS, Ulmer HG, Lorberbaum JP. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003a; 23: 15–20
   PubMed Web of Science ®Google Scholar
• Hamner MB, Faldowski RA, Ulmer HG, Frueh BC, Huber MG, Arana GW. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 2003b; 18: 1–8
   PubMed Web of Science ®Google Scholar
• Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, et al. Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–174
   PubMed Web of Science ®Google Scholar
• Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003; 182: 312–318
   PubMed Web of Science ®Google Scholar
• Hay P, Sachdev P, Cumming S, Smith JS, Lee T, Kitchener P, et al. Treatment of obsessive-compulsive disorder by psychosurgery. Acta Psychiatr Scand 1993; 87: 197–207
   PubMed Web of Science ®Google Scholar
• Hayward C, Varady S, Albano AM, Thienemann M, Henderson L, Schatzberg AF. Cognitive-behavioral group therapy for social phobia in female adolescents: results of a pilot study. J Am Acad Child Adolesc Psychiatry 2000; 39: 721–726
   PubMed Web of Science ®Google Scholar
• Heimberg RG, Dodge CS, Hope DA, Kennedy CR, Zollo L, Becker RE. Cognitive-behavioral treatment of social phobia: comparison to a credible placebo control. Cogn Ther Res 1990; 14: 1–23
   Web of Science ®Google Scholar
• Heimberg RG, Liebowitz MR, Hope DA, Schneier FR, Holt CS, Welkowitz LA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 1998; 55: 1133–1141
   PubMed Web of Science ®Google Scholar
• Heldt E, Manfro GG, Kipper L, Blaya C, Maltz S, Isolan L, et al. Treating medication-resistant panic disorder: predictors and outcome of cognitive-behavior therapy in a Brazilian public hospital. Psychother Psychosom 2003; 72: 43–48
   PubMed Web of Science ®Google Scholar
• Hembree EA, Riggs DS, Kozak MJ, Franklin ME, Foa EB. Long-term efficacy of exposure and ritual prevention therapy and serotonergic medications for obsessive-compulsive disorder. CNS Spectrums :363–371 2003; 8: 381
   Google Scholar
• Hertzberg MA, Butterfield MI, Feldman ME, Beckham JC, Sutherland SM, Connor KM, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 1999; 45: 1226–1229
   PubMed Web of Science ®Google Scholar
• Hertzberg MA, Feldman ME, Beckham JC, Kudler HS, Davidson JR. Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans. Ann Clin Psychiatry 2000; 12: 101–105
   PubMedGoogle Scholar
• Hetrick S Merry S McKenzie J Sindahl P Proctor M 2007. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev CD004851.
   Google Scholar
• Hewlett WA, Vinogradov S, Agras WS. Clomipramine, clonazepam, and clonidine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 420–430
   PubMed Web of Science ®Google Scholar
• Hidalgo RB, Tupler LA, Davidson JR. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864–872
   PubMed Web of Science ®Google Scholar
• Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J Clin Psychopharmacol 2000; 20: 556–559
   PubMed Web of Science ®Google Scholar
• Hobbs M, Mayou R, Harrison B, Worlock P. A randomised controlled trial of psychological debriefing for victims of road traffic accidents. Br Med J 1996; 313: 1438–1439
   PubMed Web of Science ®Google Scholar
• Hodgkiss AD, Malizia AL, Bartlett JR, Bridges PK. Outcome after the psychosurgical operation of stereotactic subcaudate tractotomy, 1979–1991. J Neuropsychiatry Clin Neurosci 1995; 7: 230–234
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod DR, Zimmerli WD. Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 1988; 49: 293–301
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, McLeod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993; 13: 321–326
   PubMed Web of Science ®Google Scholar
• Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, et al. Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry 2000; 57: 76–82
   PubMed Web of Science ®Google Scholar
• Hoffart A, Martinsen EW. Exposure-based integrated vs. pure psychodynamic treatment of agoraphobic inpatients. Psychotherapy 1990; 27: 210–218
   Web of Science ®Google Scholar
• Hoffart A, Due Madsen J, Lande B, Gude T, Bille H, Torgersen S. Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry 1993; 54: 481–487
   Google Scholar
• Hofmann SG. Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol 2004; 72: 393–399
   PubMed Web of Science ®Google Scholar
• Hofmann SG Smits JA. 2008. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry e1–12.
   Google Scholar
• Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298–304
   PubMed Web of Science ®Google Scholar
• Hogberg U, Wang M. Depression and pregnancy – may selective serotonin reuptake inhibitors be associated to behavioural teratogenicity? [Comment on "The obstetrician and depression during pregnancy" by Campagne DM. Eur J Obstet Gynecol Reprod Biol 2005; 120: 123–124
   Google Scholar
• Hohagen F, Winkelmann G, Rasche-Ruchle H, Hand I, Konig A, Munchau N, et al. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br J Psychiatry Suppl 1998; 35: 71–78
   Google Scholar
• Hollander E, Dell'Osso B. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. Int Clin Psychopharmacol 2006; 21: 189–191
   PubMed Web of Science ®Google Scholar
• Hollander E, Allen A, Steiner M, Wheadon DE, Oakes R, Burnham DB. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry 2003a; 64: 1113–1121
   PubMed Web of Science ®Google Scholar
• Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int J Neuropsychopharmacol 2003b; 6: 397–401
   PubMed Web of Science ®Google Scholar
• Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, et al. A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003c; 64: 640–647
   PubMed Web of Science ®Google Scholar
• Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 2005; 21: 33–40
   PubMed Web of Science ®Google Scholar
• Husain MM, Lewis SF, Thornton WL. Maintenance ECT for refractory obsessive-compulsive disorder. Am J Psychiatry 1993; 150: 1899–1900
   PubMed Web of Science ®Google Scholar
• IMCTGMSP. 1997. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71–80.
   Google Scholar
• Institute of Medicine. 2007. Treatment of PTSD: An Assessment of the Evidence. Report Brief [ www.iom.edu].
   Google Scholar
• Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53: 39–49
   PubMed Web of Science ®Google Scholar
• Ironson G, Freund B, Strauss JL, Williams J. Comparison of two treatments for traumatic stress: a community-based study of EMDR and prolonged exposure. J Clin Psychol 2002; 58: 113–128
   PubMed Web of Science ®Google Scholar
• Isolan L Pheula G Salum GA, Jr Oswald S Rohde LA Manfro GG 2007. An open-label trial of escitalopram in children and adolescents with social anxiety disorder. J Child Adolesc Psychopharmacol 17:751–760.
   PubMed Web of Science ®Google Scholar
• Jacobson AF, Dominguez RA, Goldstein BJ, Steinbook RM. Comparison of buspirone and diazepam in generalized anxiety disorder. Pharmacotherapy 1985; 5: 290–296
   PubMedGoogle Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996; 17: 1–12
   PubMedGoogle Scholar
• James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J 1984; 108: 1150–1155
   PubMed Web of Science ®Google Scholar
• James IM, Burgoyne W, Savage IT. Effect of pindolol on stress-related disturbances of musical performance: preliminary communication. J R Soc Med 1983; 76: 194–196
   PubMed Web of Science ®Google Scholar
• Jeanmonod D, Schulman J, Ramirez R, Cancro R, Lanz M, Morel A, et al. Neuropsychiatric thalamocortical dysrhythmia: surgical implications. Neurosurg Clin N Am 2003; 14: 251–265
   Google Scholar
• Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990; 147: 1209–1215
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Ballantine T, Martuza RL, Tynes S, Giriunas I, et al. Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch Gen Psychiatry 1991a; 48: 548–555
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991b; 52: 13–14
   PubMed Web of Science ®Google Scholar
• Jenike MA, Baer L, Minichiello WE, Rauch SL, Buttolph ML. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997; 154: 1261–1264
   PubMed Web of Science ®Google Scholar
• Jensen JA. An investigation of eye movement desensitization and reprocessing (EMDR) as a treatment for PTSD symptoms of Vietnam combat veterans. Behav Ther 1994; 25: 311–325
   Web of Science ®Google Scholar
• Jetty PV, Charney DS, Goddard AW. Neurobiology of generalized anxiety disorder. Psychiatr Clin N Am 2001; 24: 75–97
   PubMed Web of Science ®Google Scholar
• Johnson EM, Whyte E, Mulsant BH, Pollock BG, Weber E, Begley AE, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006; 14: 796–802
   PubMed Web of Science ®Google Scholar
• Johnston D, Troyer I, Whitsett S. Clomipramine treatment of agoraphobic women. An eight-week controlled trial. Arch Gen Psychiatry 1988; 45: 453–459
   PubMed Web of Science ®Google Scholar
• Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79: 301–308
   PubMed Web of Science ®Google Scholar
• Kamijima K, Murasaki M, Asai M, Higuchi T, Nakajima T, Taga C, et al. Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients. Psychiatry Clin Neurosci 2004; 58: 427–433
   PubMed Web of Science ®Google Scholar
• Kamijima K, Kuboki T, Kumano H, Burt T, Cohen G, Arano I, et al. A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. Int Clin Psychopharmacol 2005; 20: 265–273
   PubMed Web of Science ®Google Scholar
• Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ. A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry 2002; 63: 772–777
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005; 186: 222–226
   PubMed Web of Science ®Google Scholar
• Katz IR, Reynolds CF, Alexopoulos GS, Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc 2002; 50: 18–25
   PubMed Web of Science ®Google Scholar
• Katz RJ, DeVeaugh-Geiss J, Landau P. Clomipramine in obsessive-compulsive disorder. Biol Psychiatry 1990; 28: 401–414
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368–1371
   PubMed Web of Science ®Google Scholar
• Kawahara T, Ueda Y, Mitsuyama Y. A case report of refractory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry Clin Neurosci 2000; 54: 599–601
   PubMedGoogle Scholar
• Keane TM, Fairbank JA, Caddell JM. Implosive (flooding) therapy reduces symptoms of PTSD in combat veterans. Behav Ther 1989; 20: 245–260
   Web of Science ®Google Scholar
• Keck PE, Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry 1993; 33: 542–546
   PubMedGoogle Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005a; 62: 593–602
   PubMed Web of Science ®Google Scholar
• Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005b; 62: 617–627
   PubMed Web of Science ®Google Scholar
• Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. New Engl J Med 2005c; 352: 2515–2523
   PubMed Web of Science ®Google Scholar
• Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996; 40: 154–156
   PubMed Web of Science ®Google Scholar
• Khaldi S, Kornreich C, Dan B, Pelc I. Usefulness of olanzapine in refractory panic attacks. J Clin Psychopharmacol 2003; 23: 100–101
   Google Scholar
• Khanna S, Gangadhar BN, Sinha V, Rajendra PN, Channabasavanna SM. Electroconvulsive therapy in obsessive-compulsive disorder. Convuls Ther 1988; 4: 314–320
   PubMedGoogle Scholar
• Kim CH, Chang JW, Koo MS, Kim JW, Suh HS, Park IH, et al. Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr Scand 2003; 107: 283–290
   PubMedGoogle Scholar
• Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 211–214
   PubMed Web of Science ®Google Scholar
• Kinzie JD, Leung P. Clonidine in Cambodian patients with posttraumatic stress disorder. J Nerv Ment Dis 1989; 177: 546–550
   PubMed Web of Science ®Google Scholar
• Klein D. Delineation of two drug-responsive anxiety syndromes. Psychopharmacology 1964; 5: 397–408
   PubMed Web of Science ®Google Scholar
• Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 1993; 50: 306–317
   PubMed Web of Science ®Google Scholar
• Klein DF. Flawed meta-analyses comparing psychotherapy with pharmacotherapy. Am J Psychiatry 2000; 157: 1204–1211
   PubMed Web of Science ®Google Scholar
• Klerman GL Weissman MM Ouellette R Johnson J Greenwald S 199. Panic attacks in the community. Social Morbidity Health Care Utilization J 265:742–746.
   Google Scholar
• Klosko JS, Barlow DH, Tassinari R, Cerny JA. A comparison of alprazolam and behavior therapy in treatment of panic disorder. J Consult Clin Psychol 1990; 58: 77–84
   PubMed Web of Science ®Google Scholar
• Kobak KA, Greist JH, Jefferson JW, Katzelnick DJ. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 2002; 22: 257–262
   PubMed Web of Science ®Google Scholar
• Kobak KA, Taylor LV, Bystritsky A, Kohlenberg CJ, Greist JH, Tucker P, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 2005; 20: 299–304
   PubMed Web of Science ®Google Scholar
• Kocabasoglu N, Corapcioglu A, Yargic I, Erdogan A. Venlafaxine versus fluoxetine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12 week, controlled study [abstract]. Eur Neuropsychopharmacol 2004; 14(Suppl 3)S304
   Google Scholar
• Koponen H, Lepola U, Leinonen E, Jokinen R, Penttinen J, Turtonen J. Citalopram in the treatment of obsessive-compulsive disorder: an open pilot study. Acta Psychiatr Scand 1997; 96: 343–346
   PubMed Web of Science ®Google Scholar
• Koponen H, Allgulander C, Erickson J, Dunayevich E, Pritchett Y, Detke MJ, et al. Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians. Prim Care Companion J Clin Psychiatry 2007; 9: 100–107
   PubMedGoogle Scholar
• Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997; 154: 396–401
   PubMed Web of Science ®Google Scholar
• Koran LM, Ringold AL, Elliott MA. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry 2000; 61: 514–517
   PubMed Web of Science ®Google Scholar
• Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002; 159: 88–95
   PubMed Web of Science ®Google Scholar
• Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J Clin Psych 2005a; 66: 353–359
   Google Scholar
• Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry 2005b; 66: 515–520
   PubMed Web of Science ®Google Scholar
• Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry 2007; 164: 5–53
   PubMed Web of Science ®Google Scholar
• Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?. Can Med Assoc J 2005; 172: 1457–1459
   PubMed Web of Science ®Google Scholar
• Kosten TR, Frank JB, Dan E, McDougle CJ, Giller E. Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179: 366–370
   PubMed Web of Science ®Google Scholar
• Kronig MH, Apter J, Asnis G, Bystritsky A, Curtis G, Ferguson J, et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. J Clin Psychopharmacol 1999; 19: 172–176
   PubMed Web of Science ®Google Scholar
• Krüger MB, Dahl AA. The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 1)S19–24
   Google Scholar
• Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al. D–Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol Psychiatry 2007; 62: 835–838
   PubMed Web of Science ®Google Scholar
• Lader M, Morton S. Benzodiazepine problems. Br J Addict 1991; 86: 823–828
   PubMedGoogle Scholar
• Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berlin) 1998; 139: 402–406
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 2004; 19: 241–248
   PubMed Web of Science ®Google Scholar
• Ladouceur R, Dugas MJ, Freeston MH, Leger E, Gagnon F, Thibodeau N. Efficacy of a cognitive-behavioral treatment for generalized anxiety disorder: evaluation in a controlled clinical trial. J Consult Clin Psychol 2000; 68: 957–964
   PubMed Web of Science ®Google Scholar
• Laegreid L, Olegard R, Conradi N, Hagberg G, Wahlstrom J, Abrahamsson L. Congenital malformations and maternal consumption of benzodiazepines: a case-control study. Dev Med Child Neurol 1990; 32: 432–441
   PubMed Web of Science ®Google Scholar
• Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, et al. N-Acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berlin) 2006; 184: 254–256
   PubMed Web of Science ®Google Scholar
• Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis. J Perinatol 2005; 25: 595–604
   PubMedGoogle Scholar
• Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 153–160
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Bakker A, Dunbar G, Judge R. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 1997; 95: 145–152
   PubMed Web of Science ®Google Scholar
• Lee C, Gavriel H, Drummond P, Richards J, Greenwald R. Treatment of post-traumatic stress disorder: A comparison of stress inoculation training with prolonged exposure and eye movement desensitization and reprocessing. J Clin Psychol Psychother 2002; 58: 1071–1089
   Google Scholar
• Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 2003; 53: 772–777
   PubMed Web of Science ®Google Scholar
• Lenze EJ, Mulsant BH, Shear MK, Dew MA, Miller MD, Pollock BG, et al. Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry 2005; 162: 146–150
   PubMed Web of Science ®Google Scholar
• Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. Arch Gen Psychiatry 1989; 46: 1088–1092
   PubMed Web of Science ®Google Scholar
• Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1994; 33: 792–794
   PubMed Web of Science ®Google Scholar
• Leonardo ED, Hen R. Genetics of affective and anxiety disorders. Annu Rev Psychol 2006; 57: 117–137
   PubMed Web of Science ®Google Scholar
• Leonardo ED, Hen R. Anxiety as a developmental disorder. Neuropsychopharmacology 2008; 33: 134–140
   PubMed Web of Science ®Google Scholar
• Lepola U, Heikkinen H, Rimon R, Riekkinen P. Clinical evaluation of alprazolam in patients with panic disorder a double-blind comparison with imipramine. Hum Psychopharmacol 1990; 5: 159–163
   Google Scholar
• Lepola U, Arato M, Zhu Y, Austin C. Sertraline versus imipramine treatment of comorbid panic disorder and major depressive disorder. J Clin Psychiatry 2003; 64: 654–662
   PubMed Web of Science ®Google Scholar
• Lepola U, Bergtholdt B, St Lambert J, Davy KL, Ruggiero L. Controlled-release paroxetine in the treatment of patients with social anxiety disorder. J Clin Psychiatry 2004; 65: 222–229
   PubMed Web of Science ®Google Scholar
• Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjodin I, et al. A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 1998; 59: 528–534
   PubMed Web of Science ®Google Scholar
• Li D, Chokka P, Tibbo P. Toward an integrative understanding of social phobia. J Psychiatry Neurosci 2001; 26: 190–202
   Google Scholar
• Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. J Clin Psychiatry 2005; 66: 736–743
   PubMed Web of Science ®Google Scholar
• Lidren DM, Watkins PL, Gould RA, Clum GA, Asterino M, Tulloch HL. A comparison of bibliotherapy and group therapy in the treatment of panic disorder. J Consult Clin Psychol 1994; 62: 865–869
   PubMedGoogle Scholar
• Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987; 22: 141–173
   PubMedGoogle Scholar
• Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, et al. Pharmacotherapy of social phobia: an interim report of a placebo- controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49: 252–257
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Heimberg RG, Schneier FR, Hope DA, Davies S, Holt CS, et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999; 10: 89–98
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Stein MB, Tancer M, Carpenter D, Oakes R, Pitts CD. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002a; 63: 66–74
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies SO, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002b; 41: 1431–1438
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005a; 62: 190–198
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Mangano RM, Bradwejn J, Asnis G. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005b; 66: 238–247
   PubMed Web of Science ®Google Scholar
• Linden M, Zubraegel D, Baer T, Franke U, Schlattmann P. Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study). Psychother Psychosom 2005; 74: 36–42
   PubMed Web of Science ®Google Scholar
• Lindsay M, Crino R, Andrews G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiatry 1997; 171: 135–139
   PubMed Web of Science ®Google Scholar
• Lindsay WR, Gamsu CV, McLaughlin E, Hood EM, Espie CA. A controlled trial of treatments for generalized anxiety. Br J Clin Psychol 1987; 26: 3–15
   PubMed Web of Science ®Google Scholar
• Lipper S, Davidson JR, Grady TA, Edinger JD, Hammett EB, Mahorney SL, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849–854
   PubMed Web of Science ®Google Scholar
• Lippitz BE, Mindus P, Meyerson BA, Kihlstrom L, Lindquist C. Lesion topography and outcome after thermocapsulotomy or gamma knife capsulotomy for obsessive-compulsive disorder: relevance of the right hemisphere. Neurosurgery 1999; 44: 452–858
   PubMed Web of Science ®Google Scholar
• Livingston MG. Benzodiazepine dependence. Br J Hosp Med 1994; 51: 281–286
   PubMed Web of Science ®Google Scholar
• Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, et al. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study. J Clin Psychiatry 2002; 63: 1020–1027
   PubMed Web of Science ®Google Scholar
• Loerch B, Graf-Morgenstern M, Hautzinger M, Schlegel S, Hain C, Sandmann J, et al. Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 1999; 174: 205–212
   PubMed Web of Science ®Google Scholar
• Londborg PD, Wolkow R, Smith WT, DuBoff E, England D, Ferguson J, et al. Sertraline in the treatment of panic disorder – A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 1998; 173: 54–60
   PubMed Web of Science ®Google Scholar
• Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, et al. Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 2001; 62: 325–331
   PubMed Web of Science ®Google Scholar
• Lopes AC, Taub A, D'Alcante CC, Mathis ME, Hoexter MQ, Gouvea FS, et al. Gamma ventral capsulotomy for obsessive compulsive-disorder: Preliminary results of a randomized controlled trial. Biol Psychiaty 2008; 63: 131s
   Google Scholar
• López-Ibor JJ, López-Ibor Aliño JJ. Selection criteria for patients who must undergo psychiatric surgery. Neurological treatment in psychiatry, pain and epilepsy, WH Sweet, S Obrador, JG Martín-Rodríguez. University Park Press, Baltimore, MD 1975; 151–162
   Google Scholar
• Lopez-Ibor JJ, Saiz J, Cottraux J, Note I, Vinas R, Bourgeois M, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996; 6: 111–118
   PubMed Web of Science ®Google Scholar
• Lum M, Fontaine R, Elie R, Ontiveros A. Divalproex sodium's antipanic effect in panic disorder: a placebo-controlled study. Biol Psychiatry :A 1990; 27: 164–165
   Google Scholar
• Lundberg S, Carlsson A, Norfeldt P, Carlsson ML. Nicotine treatment of obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1195–1199
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992; 12: 96–103
   PubMedGoogle Scholar
• Lydiard RB, Ballenger JC, Rickels K. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group. J Clin Psychiatry 1997; 58: 11–18
   PubMedGoogle Scholar
• Maina G, Pessina E, Albert U, Bogetto F. 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur Neuropsychopharmacol 2008; 18: 364–372
   PubMed Web of Science ®Google Scholar
• Malek-Ahmadi P. Gabapentin and posttraumatic stress disorder. Ann Pharmacother 2003; 37: 664–666
   Google Scholar
• Maletzky B, McFarland B, Burt A. Refractory obsessive compulsive disorder and ECT. Convuls Ther 1994; 10: 34–42
   PubMedGoogle Scholar
• Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 1289–1296
   PubMed Web of Science ®Google Scholar
• Mantovani A, Lisanby SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive–compulsive disorder (OCD) and Tourette's syndrome (TS). Int J Neuropsychopharmacol 2006; 9: 95–100
   PubMed Web of Science ®Google Scholar
• Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999; 156: 1834–1835
   PubMed Web of Science ®Google Scholar
• Marazziti D, Dell'Osso L, Gemignani A, Ciapparelli A, Presta S, Nasso ED, et al. Citalopram in refractory obsessive-compulsive disorder: an open study. Int Clin Psychopharmacol 2001; 16: 215–219
   PubMedGoogle Scholar
• Marazziti D, Pfanner C, Dell'Osso B, Ciapparelli A, Presta S, Corretti G, et al. Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. J Psychopharmacol 2005; 19: 392–394
   PubMed Web of Science ®Google Scholar
• March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. J Am Med Assoc 1998; 280: 1752–1756
   PubMed Web of Science ®Google Scholar
• March JS, Entusah AR, Rynn M, Albano AM, Tourian KA. A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 2007; 62: 1149–1154
   PubMed Web of Science ®Google Scholar
• Marcus S, Marquis P, Sakai C. Controlled study of treatment of PTSD using EMDR in an HMO setting. Psychotherapy 1997; 34: 307–315
   Web of Science ®Google Scholar
• Margraf J, Barlow DH, Clark DM, Telch MJ. Psychological treatment of panic: work in progress on outcome, active ingredients, and follow-up. Behav Res Ther 1993; 31: 1–8
   PubMed Web of Science ®Google Scholar
• Markovitz PJ, Stagno SJ, Calabrese JR. Buspirone augmentation of fluoxetine in obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 798–800
   PubMed Web of Science ®Google Scholar
• Marks I, Lovell K, Noshirvani H, Livanou M, Thrasher S. Treatment of posttraumatic stress disorder by exposure and/or cognitive restructuring: a controlled study. Arch Gen Psychiatry 1998; 55: 317–325
   PubMed Web of Science ®Google Scholar
• Marks IM, Stern RS, Mawson D, Cobb J, McDonald R. Clomipramine and exposure for obsessive-compulsive rituals: I. Br J Psychiatry 1980; 136: 1–25
   PubMed Web of Science ®Google Scholar
• Marks IM, Gray S, Cohen D, Hill R, Mawson D, Ramm E, et al. Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework. Arch Gen Psychiatry 1983; 40: 153–162
   PubMed Web of Science ®Google Scholar
• Marks IM. Fears, phobias and rituals. Oxford University Press, New York, Oxford 1987
   Google Scholar
• Marks IM, Lelliott P, Basoglu M, Noshirvani H, Monteiro W, Cohen D, et al. Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. Br J Psychiatry 1988; 152: 522–534
   PubMed Web of Science ®Google Scholar
• Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, et al. Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br J Psychiatry 1993; 162: 776–787
   PubMed Web of Science ®Google Scholar
• Marmar CR, Schoenfeld F, Weiss DS, Metzler T, Zatzick D, Wu R, et al. Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 1996; 57(Suppl 8)66–70
   PubMedGoogle Scholar
• Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, et al. An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998; 18: 10–18
   PubMed Web of Science ®Google Scholar
• Marshall RD, Beebe KL, Oldham M, Zaninelli R. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 2001; 158: 1982–1988
   PubMed Web of Science ®Google Scholar
• Martenyi F, Soldatenkova V. Fluoxetine in the acute treatment and relapse prevention of combat-related post-traumatic stress disorder: Analysis of the veteran group of a placebo-controlled, randomized clinical trial. Eur Neuropsychopharmacol 2006; 16: 340–349
   Web of Science ®Google Scholar
• Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 2002a; 181: 315–320
   PubMed Web of Science ®Google Scholar
• Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 2002b; 63: 199–206
   PubMed Web of Science ®Google Scholar
• Martenyi F, Brown EB, Caldwell CD. Failed efficacy of fluoxetine in the treatment of posttraumatic stress disorder: results of a fixed-dose, placebo-controlled study. J Clin Psychopharmacol 2007; 27: 166–170
   PubMed Web of Science ®Google Scholar
• Mattick RP, Andrews G, Hadzi-Pavlovic D, Christensen H. Treatment of panic and agoraphobia. An integrative review. J Nerv Ment Dis 1990; 178: 567–576
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Michelson L. Agoraphobia: behavioral and pharmacological treatment (n = 49). Psychopharmacol Bull 1983; 19: 116–118
   Google Scholar
• Mavissakalian M, Michelson L. Agoraphobia – relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine. J Clin Psychol 1986; 47: 117–122
   Google Scholar
• Mavissakalian M, Michelson L, Dealy RS. Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice. Br J Psychiatry 1983; 143: 348–355
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel JM. Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 1992a; 149: 1053–1057
   PubMed Web of Science ®Google Scholar
• Mavissakalian M, Perel JM. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1992b; 49: 318–323
   PubMed Web of Science ®Google Scholar
• Mayou RA, Ehlers A, Hobbs M. Psychological debriefing for road traffic accident victims. Three-year follow-up of a randomised controlled trial. Br J Psychiatry 2000; 176: 589–593
   PubMed Web of Science ®Google Scholar
• Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007; 22: 129–133
   PubMed Web of Science ®Google Scholar
• McDonagh A, Friedman M, McHugo G, Ford J, Sengupta A, Mueser K, et al. Randomized trial of cognitive–behavioral therapy for chronic posttraumatic stress disorder in adult female survivors of childhood sexual abuse. J Consult Clin Psychol 2005; 73: 515–524
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990; 147: 652–654
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11: 175–184
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 1994; 51: 302–308
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000; 57: 794–801
   PubMed Web of Science ®Google Scholar
• McLean PD, Whittal ML, Thordarson DS, Taylor S, Sochting I, Koch WJ, et al. Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder. J Consult Clin Psychol 2001; 69: 205–214
   PubMed Web of Science ®Google Scholar
• McRae AL, Brady KT, Mellman TA, Sonne SC, Killeen TK, Timmerman MA, et al. Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. Depress Anxiety 2004; 19: 190–196
   PubMed Web of Science ®Google Scholar
• Meibach RC, Dunner D, Wilson LG, Ishiki D, Dager SR. Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety: a double-blind trial. J Clin Psychiatry 1987; 48: 355–358
   PubMed Web of Science ®Google Scholar
• Mellman LA, Gorman JM. Successful treatment of obsessive-compulsive disorder with ECT. Am J Psychiatry 1984; 141: 596–597
   Web of Science ®Google Scholar
• Mellman TA, Bustamante V, David D, Fins AI. Hypnotic medication in the aftermath of trauma. J Clin Psychiatry 2002; 63: 1183–1184
   PubMed Web of Science ®Google Scholar
• Meltzer-Brody S, Connor KM, Churchill E, Davidson JR. Symptom-specific effects of fluoxetine in post-traumatic stress disorder. Int Clin Psychopharmacol 2000; 15: 227–231
   Google Scholar
• Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, et al. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 1998; 155: 1570–1577
   PubMed Web of Science ®Google Scholar
• Michelson D, Allgulander C, Dantendorfer K, Knezevic A, Maierhofer D, Micev V, et al. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 2001; 179: 514–518
   PubMed Web of Science ®Google Scholar
• Michelson L, Mavissakalian M, Marchione K. Cognitive, behavioral, and psychophysiological treatments of agoraphobia – a comparative outcome investigation. Behav Ther 1988; 19: 97–120
   Web of Science ®Google Scholar
• Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). Nord J Psychiatry 2004; 58: 65–70
   PubMed Web of Science ®Google Scholar
• Milanfranchi A, Ravagli S, Lensi P, Marazziti D, Cassano GB. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997; 12: 131–136
   PubMed Web of Science ®Google Scholar
• Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M, Clarkin J, et al. A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. Am J Psychiatry 2007; 164: 265–272
   PubMed Web of Science ®Google Scholar
• Mindus P, Nyman H, Mogard J. Frontal lobe and basal ganglia metabolism studied with PET in patients with incapacitating obsessive-compulsive disorder undergoing capsulotomy. Nord Psykiatr Tidsskr 1990; 44: 309–312
   Google Scholar
• Mindus P, Edman G, Andreewitch S. A prospective, long-term study of personality traits in patients with intractable obsessional illness treated by capsulotomy. Acta Psychiatr Scand 1999; 99: 40–50
   PubMed Web of Science ®Google Scholar
• Misri S, Burgmann A, Kostaras D. Are SSRIs safe for pregnant and breastfeeding women?. Can Family Phys 2000a; 46: 626–628
   PubMedGoogle Scholar
• Misri S, Kostaras D, Kostaras X. The use of selective serotonin reuptake inhibitors during pregnancy and lactation: Current knowledge. Can J Psych 2000b; 45: 285–287
   Google Scholar
• Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005; 88: 27–45
   PubMed Web of Science ®Google Scholar
• Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992; 12: 251–261
   Google Scholar
• Mohlman J, Gorenstein EE, Kleber M, de Jesus M, Gorman JM, Papp LA. Standard and enhanced cognitive-behavior therapy for late-life generalized anxiety disorder: two pilot investigations. Am J Geriatr Psychiatry 2003; 11: 24–32
   PubMed Web of Science ®Google Scholar
• Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002; 17: 37–40
   PubMed Web of Science ®Google Scholar
• Möller HJ, Volz HP, Reimann IW, Stoll KD. Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 2001; 21: 59–65
   PubMed Web of Science ®Google Scholar
• Monnelly EP, Ciraulo DA, Knapp C, Keane T. Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 2003; 23: 193–196
   PubMed Web of Science ®Google Scholar
• Montgomery SA, McIntyre A, Osterheider M, Sarteschi P, Zitterl W, Zohar J, et al. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur Neuropsychopharmacol 1993; 3: 143–152
   PubMedGoogle Scholar
• Montgomery SA, Kasper S, Stein DJ, Bang Hedegaard K, Lemming OM. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001; 16: 75–86
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–1278
   PubMed Web of Science ®Google Scholar
• Montgomery SA Chalmers K Baldinetti F Whalen E. 2006a. Efficacy and safety of pregabalin for the treatment of generalized anxiety disorder in elderly patients (Poster). 19th European College of Neuropsychopharmacology Congress. 16–20 September, Nice, France.
   Google Scholar
• Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry 2006b; 67: 771–782
   PubMed Web of Science ®Google Scholar
• Montoya A, Weiss AP, Price BH, Cassem EH, Dougherty DD, Nierenberg AA, et al. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery 2002; 50: 1043–1049
   PubMed Web of Science ®Google Scholar
• Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1735–1740
   PubMed Web of Science ®Google Scholar
• Moroz G, Rosenbaum JF. Efficacy, safety, and gradual discontinuation of clonazepam in panic disorder: a placebo-controlled, multicenter study using optimized dosages. J Clin Psychiatry 1999; 60: 604–612
   PubMed Web of Science ®Google Scholar
• Mortberg E, Karlsson A, Fyring C, Sundin O. Intensive cognitive-behavioral group treatment (CBGT) of social phobia: a randomized controlled study. J Anxiety Disord 2006; 20: 646–660
   PubMed Web of Science ®Google Scholar
• Mortberg E, Clark DM, Sundin O, Aberg Wistedt A. Intensive group cognitive treatment and individual cognitive therapy vs. treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatr Scand 2007; 115: 142–154
   PubMed Web of Science ®Google Scholar
• Muehlbacher M, Nickel MK, Nickel C, Kettler C, Lahmann C, Pedrosa Gil F, et al. Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 580–583
   PubMed Web of Science ®Google Scholar
• Mukaddes NM, Abali O, Kaynak N. Citalopram treatment of children and adolescents with obsessive-compulsive disorder: a preliminary report. Psychiatry Clin Neurosci 2003; 57: 405–408
   PubMedGoogle Scholar
• Mundo E, Guglielmo E, Bellodi L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 1998; 13: 219–224
   PubMed Web of Science ®Google Scholar
• Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000; 15: 69–76
   PubMed Web of Science ®Google Scholar
• Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, et al. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989; 9: 22–27
   PubMed Web of Science ®Google Scholar
• Munjack DJ, Baltazar PL, Bohn PB, Cabe DD, Appleton AA. Clonazepam in the treatment of social phobia: a pilot study. J Clin Psychiatry 1990; 51(Suppl 5)35–40
   Google Scholar
• Murphy MT, Michelson LK, Marchione K, Marchione N, Testa S. The role of self-directed in vivo exposure in combination with cognitive therapy, relaxation training, or therapist-assisted exposure in the treatment of panic disorder with agoraphobia. J Anxiety Disord 1998; 12: 117–138
   PubMed Web of Science ®Google Scholar
• Nagy LM, Krystal JH, Woods SW, Charney DS. Clinical and medication outcome after short-term alprazolam and behavioral group treatment in panic disorder. 2.5 year naturalistic follow-up study. Arch Gen Psychiatry 1989; 46: 993–999
   PubMed Web of Science ®Google Scholar
• Nair NP, Bakish D, Saxena B, Amin M, Schwartz G, West TE. Comparison of fluvoxamine, imipramine, and placebo in the treatment of outpatients with panic disorder. Anxiety 1996; 2: 192–198
   PubMedGoogle Scholar
• Nakatani E, Nakagawa A, Nakao T, Yoshizato C, Nabeyama M, Kudo A, et al. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder – effectiveness of behavior therapy and fluvoxamine. Psychother Psychosom 2005; 74: 269–276
   PubMed Web of Science ®Google Scholar
• Neal LA, Shapland W, Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol 1997; 12: 231–237
   PubMed Web of Science ®Google Scholar
• Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Can Soc Clin Pharmacol 1999; 6: 69–83
   PubMedGoogle Scholar
• Neuner F, Schauer M, Klaschik C, Karunakara U, Elbert T. A comparison of narrative exposure therapy, supportive counseling, and psychoeducation for treating posttraumatic stress disorder in an African refugee settlement. J Consult Clin Psychol 2004; 72: 579–587
   PubMed Web of Science ®Google Scholar
• Neylan TC, Metzler TJ, Schoenfeld FB, Weiss DS, Lenoci M, Best SR, et al. Fluvoxamine and sleep disturbances in posttraumatic stress disorder. J Trauma Stress 2001; 14: 461–467
   Web of Science ®Google Scholar
• Neylan TC, Lenoci M, Samuelson KW, Metzler TJ, Henn-Haase C, Hierholzer RW, et al. No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 2006; 163: 2186–2188
   PubMed Web of Science ®Google Scholar
• NICE 2005 National Institute for Clinical Excellence (NICE): Post-traumatic Stress Disorder. The management of PTSD in adults and children in primary and secondary care.
   Google Scholar
• NICE 2006. National Institute for Clinical Excellence (NICE): Obsessive compulsive disorder: Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder.
   Google Scholar
• NICE 2007. National Institute for Health and Clinical Excellence (NICE). Anxiety (amended): Management of Anxiety (Panic Disorder, with or without Agoraphobia, and Generalised Anxiety Disorder) in Adults in Primary, Secondary and Community Care.
   Google Scholar
• Nicolini H Bakish D Duenas H Spann M Erickson J Hallberg C, et al 2008. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial. Psychol Med 1–10.
   Google Scholar
• Nimatoudis I, Zissis NP, Kogeorgos J, Theodoropoulou S, Vidalis A, Kaprinis G. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol 2004; 19: 331–336
   PubMed Web of Science ®Google Scholar
• NIMH 1976. National Institute of Mental Health. 028 CGI. Clinical Global Impressions. In: Guy E, ECDEU Assessment manual for psychopharmacology. Revised edition. Rockville, MD: NIMH. p 217–222.
   Google Scholar
• Ninan PT, Koran LM, Kiev A, Davidson JR, Rasmussen SA, Zajecka JM, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006; 67: 15–22
   PubMed Web of Science ®Google Scholar
• Norberg MM, Krystal JH, Tolin DF. A meta-analysis of d-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry 2008; 63: 1118–26
   PubMed Web of Science ®Google Scholar
• Nordeng H, Spigset O. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy: effects on the infant. Drug Saf 2005; 28: 565–581
   Google Scholar
• Norton PJ, Price EC. A meta-analytic review of adult cognitive-behavioral treatment outcome across the anxiety disorders. J Nerv Ment Dis 2007; 195: 521–531
   PubMed Web of Science ®Google Scholar
• Noyes R, Anderson DJ, Clancy J, Crowe RR, Slymen DJ, Ghoneim MM, et al. Diazepam and propranolol in panic disorder and agoraphobia. Arch Gen Psychiatry 1984; 41: 287–292
   PubMed Web of Science ®Google Scholar
• Noyes R, Burrows GD, Reich JH, Judd FK, Garvey MJ, Norman TR, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996; 57: 349–355
   PubMed Web of Science ®Google Scholar
• Noyes R, Moroz G, Davidson JR, Liebowitz MR, Davidson A, Siegel J, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17: 247–254
   PubMed Web of Science ®Google Scholar
• Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889–1895
   PubMed Web of Science ®Google Scholar
• Nutt D, Allgulander C, Lecrubier Y, Peters T, Wittchen U. Establishing non-inferiority in treatment trials in psychiatry – guidelines from an Expert Consensus Meeting. J Psychopharmacol 2008; 22: 409–416
   PubMedGoogle Scholar
• Nutt DJ. Death by tricyclic: the real antidepressant scandal?. J Psychopharmacol 2005; 19: 123–124
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Sharpe M. Uncritical positive regard? Issues in the efficacy and safety of psychotherapy. J Psychopharmacol 2008; 22: 3–6
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Bell CJ, Malizia AL. Brain mechanisms of social anxiety disorder. J Clin Psychiatry 1998; 59(Suppl 17)4–11
   PubMed Web of Science ®Google Scholar
• Nuttin B, Cosyns P, Demeulemeester H, Gybels J, Meyerson B. Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 1999; 354: 1526
   PubMed Web of Science ®Google Scholar
• Nuttin BJ, Gabriels LA, Cosyns PR, Meyerson BA, Andreewitch S, Sunaert SG, et al. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery 2003; 52: 1263–1272
   PubMed Web of Science ®Google Scholar
• O'Connor KP, Aardema F, Robillard S, Guay S, Pelissier MC, Todorov C, et al. Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder. Acta Psychiatr Scand 2006; 113: 408–419
   Google Scholar
• Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. Br J Psychiatry 2008; 192: 338–343
   PubMed Web of Science ®Google Scholar
• Oehrberg S, Christiansen PE, Behnke K, Borup AL, Severin B, Soegaard J, et al. Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 1995; 167: 374–379
   PubMed Web of Science ®Google Scholar
• Oliver B, Gascon J, Aparicio A, Ayats E, Rodriguez R, Maestro De Leon JL, et al. Bilateral anterior capsulotomy for refractory obsessive-compulsive disorders. Stereotact Funct Neurosurg 2003; 81: 90–95
   PubMed Web of Science ®Google Scholar
• Onder E, Tural U, Aker T. A comparative study of fluoxetine, moclobemide, and tianeptine in the treatment of posttraumatic stress disorder following an earthquake. Eur Psychiatry 2006; 21: 174–179
   Google Scholar
• Onder E, Tural U, Gokbakan M. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?. Eur Arch Psychiatry Clin Neurosci 2008; 258: 319–23
   Google Scholar
• Ontiveros A, Fontaine R. Sodium valproate and clonazepam for treatment-resistant panic disorder. J Psychiatry Neurosci 1992; 17: 78–80
   Web of Science ®Google Scholar
• Öst LG, Breitholtz E. Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. Behav Res Ther 2000; 38: 777–790
   PubMed Web of Science ®Google Scholar
• Otsuka T, Togo T, Sugiyama N, Uehara K, Yoshimi A, Karashima A, et al. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 564–566
   Google Scholar
• Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993; 150: 1485–1490
   PubMed Web of Science ®Google Scholar
• Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001; 158: 1989–1992
   PubMed Web of Science ®Google Scholar
• Padala PR, Madison J, Monnahan M, Marcil W, Price P, Ramaswamy S, et al. Risperidone monotherapy for post-traumatic stress disorder related to sexual assault and domestic abuse in women. Int Clin Psychopharmacol 2006; 21: 275–280
   PubMed Web of Science ®Google Scholar
• Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol 2001; 21: 335–339
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L. Resistant social anxiety disorder response to Escitalopram. Clin Pract Epidemiol Ment Health 2006; 2: 35
   PubMedGoogle Scholar
• Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry 1999; 14: 101–106
   PubMed Web of Science ®Google Scholar
• Pallanti S, Quercioli L, Bruscoli M. Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study. J Clin Psychiatry 2004; 65: 1394–1399
   PubMed Web of Science ®Google Scholar
• Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999; 19: 341–348
   PubMed Web of Science ®Google Scholar
• Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 2000; 20: 467–471
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 2003; 160: 533–540
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141–149
   PubMed Web of Science ®Google Scholar
• Pasquini M, Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1173–1175
   PubMed Web of Science ®Google Scholar
• Pastrana Jiménez JI, Catalina Romero C, García Diéguez N, López-Ibor Aliño JJ. Pharmacological treatment of acute stress disorder with propranolol and hypnotics. Actas Esp Psiquiatr 2007; 35: 351–358
   Google Scholar
• Pediatric OCD Treatment Study Group. 2004. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. J Am Med Assoc 292:1969–1976.
   Google Scholar
• Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2001; 34: 85–90
   PubMed Web of Science ®Google Scholar
• Peskind ER, Bonner LT, Hoff DJ, Raskind MA. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol 2003; 16: 165–171
   PubMed Web of Science ®Google Scholar
• Petty F, Brannan S, Casada J, Davis LL, Gajewski V, Kramer GL, et al. Olanzapine treatment for post-traumatic stress disorder: an open-label study. Int Clin Psychopharmacol 2001; 16: 331–337
   PubMed Web of Science ®Google Scholar
• Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, et al. Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study. Int Clin Psychopharmacol 2000; 15: 297–301
   PubMed Web of Science ®Google Scholar
• Piccinelli M, Pini S, Bellantuono C, Wilkinson G. Efficacy of drug treatment in obsessive-compulsive disorder. A metaanalytic review. Br J Psychiatry 1995; 166: 424–443
   PubMed Web of Science ®Google Scholar
• Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 1999; 60: 101–106
   PubMed Web of Science ®Google Scholar
• Pigott TA, L'Heureux F, Hill JL, Bihari K, Bernstein SE, Murphy DL. A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1992; 12: 11–18
   PubMed Web of Science ®Google Scholar
• Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, et al. Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 2002; 51: 189–192
   PubMed Web of Science ®Google Scholar
• Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: A double-blind multicenter trial. Am J Psychiatry 1998; 155: 1189–1195
   PubMed Web of Science ®Google Scholar
• Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 2005; 25: 151–158
   PubMed Web of Science ®Google Scholar
• Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 2007a; 194: 233–242
   PubMed Web of Science ®Google Scholar
• Pollack MH, Doyle AC. Treatment of panic disorder: focus on paroxetine. Psychopharmacol Bull 2003; 37(Suppl 1)53–63
   Google Scholar
• Pollack MH, Otto MW, Tesar GE, Cohen LS, Meltzer Brody S, Rosenbaum JF. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol 1993; 13: 257–263
   PubMed Web of Science ®Google Scholar
• Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry 1994; 55: 200–205
   PubMed Web of Science ®Google Scholar
• Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32: 667–670
   PubMed Web of Science ®Google Scholar
• Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry 1997; 58(Suppl 11)19–23
   PubMedGoogle Scholar
• Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry 1998; 55: 1010–1016
   PubMed Web of Science ®Google Scholar
• Pollack MH, Zaninelli R, Goddard A, McCafferty JP, Bellew KM, Burnham DB, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 350–357
   PubMed Web of Science ®Google Scholar
• Pollack MH, Allgulander C, Bandelow B, Cassano GB, Greist JH, Hollander E, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectrums 2003a; 8: 17–30
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Worthington JJ, Doyle AL, Peters P, Toshkov F, et al. Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol 2003b; 17: 276–282
   PubMed Web of Science ®Google Scholar
• Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, et al. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 2005; 66: 1401–1408
   PubMed Web of Science ®Google Scholar
• Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry 2006; 59: 211–215
   PubMed Web of Science ®Google Scholar
• Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24: 1–14
   PubMed Web of Science ®Google Scholar
• Pollack MH, Tiller J, Xie F, Trivedi MH. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J Clin Psychopharmacol 2008; 28: 308–316
   PubMed Web of Science ®Google Scholar
• Pols H, Zandergen J, de Loof C, Fernandez I, Griez E. Clinical effects of fluvoxamine on panic symptomatology. Acta Psychiatr Belg 1993; 93: 169–177
   Google Scholar
• Power KG, Simpson RJ, Swanson V, Wallace LA. Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract 1990; 40: 289–294
   PubMed Web of Science ®Google Scholar
• Power KG, McGoldrick T, Brown K. A controlled comparison of eye movement desensitization and reprocessing versus exposure plus cognitive restructuring, versus waiting list in the treatment of post-traumatic stress disorder. J Clin Psychol Psychother 2002; 9: 299–318
   Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A, Koran L. Memantine for treatment-resistant OCD. Am J Psychiatry 2005; 162: 2191–2192
   PubMed Web of Science ®Google Scholar
• Prasko J, Dockery C, Horacek J, Houbova P, Kosova J, Klaschka J, et al. Moclobemide and cognitive behavioral therapy in the treatment of social phobia. A six-month controlled study and 24 months follow up. Neuroendocrinol Lett 2006a; 27: 473–481
   Google Scholar
• Prasko J, Paskova B, Zalesky R, Novak T, Kopecek M, Bares M, et al. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuroendocrinol Lett 2006b; 27: 327–332
   PubMed Web of Science ®Google Scholar
• Preter M, Klein DF. Panic, suffocation false alarms, separation anxiety and endogenous opioids. Progress Neuro-Psychopharmacol BiolPsychiatry 2008; 32: 603–612
   PubMed Web of Science ®Google Scholar
• Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol 1996; 42: 757–763
   PubMed Web of Science ®Google Scholar
• Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry 1990; 35: 248–250
   PubMed Web of Science ®Google Scholar
• Rabinowitz I, Baruch Y, Barak Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008; 23: 49–53
   PubMed Web of Science ®Google Scholar
• Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008; 192: 344–350
   PubMed Web of Science ®Google Scholar
• Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, et al. Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress Anxiety 2001; 14: 255–262
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 2001; 104: 289–298
   PubMed Web of Science ®Google Scholar
• Rapoport JL, Inoff-Germain G. Treatment of obsessive-compulsive disorder in children and adolescents. J Child Psychol Psychiatry 2000; 41: 419–431
   PubMed Web of Science ®Google Scholar
• Raskind MA, Dobie DJ, Kanter ED, Petrie EC, Thompson CE, Peskind ER. The alpha1-adrenergic antagonist prazosin ameliorates combat trauma nightmares in veterans with posttraumatic stress disorder: a report of 4 cases. J Clin Psychiatry 2000; 61: 129–133
   Google Scholar
• Raskind MA, Thompson C, Petrie EC, Dobie DJ, Rein RJ, Hoff DJ, et al. Prazosin reduces nightmares in combat veterans with posttraumatic stress disorder. J Clin Psychiatry 2002; 63: 565–568
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Kanter ED, Petrie EC, Radant A, Thompson CE, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 2003; 160: 371–373
   PubMed Web of Science ®Google Scholar
• Rasmussen S, Hackett E, DuBoff E, Greist J, Halaris A, Koran LM, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997; 12: 309–316
   PubMed Web of Science ®Google Scholar
• Rasmussen SA. Lithium and tryptophan augmentation in clomipramine-resistant obsessive-compulsive disorder. Am J Psychiatry 1984; 141: 1283–1285
   PubMed Web of Science ®Google Scholar
• Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J Clin Psychopharmacol 1991; 11: 344–350
   PubMed Web of Science ®Google Scholar
• Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol Bull 1996; 32: 677–682
   PubMedGoogle Scholar
• Reist C, Kauffmann CD, Haier RJ, Sangdahl C, DeMet EM, Chicz-DeMet A, et al. A controlled trial of desipramine in 18 men with posttraumatic stress disorder. Am J Psychiatry 1989; 146: 513–516
   PubMed Web of Science ®Google Scholar
• Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA. A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims. J Consult Clin Psychol 2002; 70: 867–879
   PubMed Web of Science ®Google Scholar
• Ressler KJ, Mayberg HS. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007; 10: 1116–1124
   PubMed Web of Science ®Google Scholar
• Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, et al. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 2001; 34: 1303–1307
   PubMed Web of Science ®Google Scholar
• Rice DP Miller LS 1998. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl 4–9.
   Google Scholar
• Richter EO, Davis KD, Hamani C, Hutchison WD, Dostrovsky JO, Lozano AM. Cingulotomy for psychiatric disease: microelectrode guidance, a callosal reference system for documenting lesion location, and clinical results. Neurosurgery 2004; 54: 622–628
   PubMed Web of Science ®Google Scholar
• Rickels K. Benzodiazepines in the treatment of anxiety. Am J Psychother 1982; 36: 358–370
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E. Panic disorder: long-term pharmacotherapy and discontinuation. J Clin Psychopharmacol :S 1998; 18: 12–18
   PubMed Web of Science ®Google Scholar
• Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982; 43: 81–86
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990; 47: 899–907
   PubMed Web of Science ®Google Scholar
• Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993; 50: 884–895
   PubMed Web of Science ®Google Scholar
• Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C. Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 1997; 17: 272–277
   PubMed Web of Science ®Google Scholar
• Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol 2000a; 20: 12–18
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000b; 157: 968–974
   PubMed Web of Science ®Google Scholar
• Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749–756
   PubMed Web of Science ®Google Scholar
• Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 488–496
   PubMed Web of Science ®Google Scholar
• Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005; 62: 1022–1030
   PubMed Web of Science ®Google Scholar
• Rickels K, Mathew S, Banov MD, Zimbroff DL, Oshana S, Parsons EC, et al. Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28: 235–239
   PubMed Web of Science ®Google Scholar
• Riddle MA, Scahill L, King RA, Hardin MT, Anderson GM, Ort SI, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992; 31: 1062–1069
   PubMed Web of Science ®Google Scholar
• Riddle MA, Claghorn JL, Gaffney G, Griest JH, Holland AD, Landbloom R, et al. A controlled trial of fluvoxamine for obsessive-compulsive disorder in children and adolescents. Psychopharmacol Bull 1996; 32: 399
   Google Scholar
• Riddle MA, Reeve EA, Yaryura-Tobias JA, Yang HM, Claghorn JL, Gaffney G, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40: 222–229
   PubMed Web of Science ®Google Scholar
• Rizley R, Kahn RJ, McNair DM, Frankenthaler LM. A comparison of alprazolam and imipramine in the treatment of agoraphobia and panic disorder. Psychopharmacol Bull 1986; 22: 167–172
   PubMed Web of Science ®Google Scholar
• Robert S, Hamner MB, Ulmer HG, Lorberbaum JP, Durkalski VL. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006; 67: 1522–1526
   PubMed Web of Science ®Google Scholar
• Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997; 95: 444–450
   PubMed Web of Science ®Google Scholar
• Rogers JM, Read CA. Psychiatric comorbidity following traumatic brain injury. Brain Inj 2007; 21: 1321–1333
   PubMed Web of Science ®Google Scholar
• Romano S, Goodman W, Tamura R, Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J Clin Psychopharmacol 2001; 21: 46–52
   PubMed Web of Science ®Google Scholar
• Roose SP. Treatment of depression in patients with heart disease. Biol Psychiatry 2003; 54: 262–268
   PubMed Web of Science ®Google Scholar
• Rose S, Brewin CR, Andrews B, Kirk M. A randomized controlled trial of individual psychological debriefing for victims of violent crime. Psychol Med 1999; 29: 793–799
   PubMed Web of Science ®Google Scholar
• Rosenbaum JF, Moroz G, Bowden CL. Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 1997; 17: 390–400
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Stewart CM, Fitzgerald KD, Tawile V, Carroll E. Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1180–1185
   PubMed Web of Science ®Google Scholar
• Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry 2003; 64: 1245–1249
   PubMed Web of Science ®Google Scholar
• Ross CA, Matas M. A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can J Psychiatry 1987; 32: 351–355
   PubMedGoogle Scholar
• Rothbaum B. A controlled study of eye movement desensitization and reprocessing in the treatment of post-traumatic stress disordered sexual assault victims. Bull Menninger Clinic 1997; 61: 317–334
   PubMed Web of Science ®Google Scholar
• Rothbaum BO, Cahill SP, Foa EB, Davidson JR, Compton J, Connor KM, et al. Augmentation of sertraline with prolonged exposure in the treatment of posttraumatic stress disorder. J Trauma Stress 2006; 19: 625–638
   PubMed Web of Science ®Google Scholar
• Rothbaum BO Killeen TK Davidson JR Brady KT Connor KM Heekin MH. 2008. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry e1–6.
   Google Scholar
• Rubio G, Lopez-Ibor JJ. Generalized anxiety disorder: a 40-year follow-up study. Acta Psychiatr Scand 2007a; 115: 372–379
   PubMed Web of Science ®Google Scholar
• Rubio G, Lopez-Ibor JJ. What can be learnt from the natural history of anxiety disorders?. Eur Psychiatry 2007b; 22: 80–86
   PubMed Web of Science ®Google Scholar
• Rück C. Capsulotomy in anxiety disorders [thesis]. Karolinska University, Stockholm 2006
   Google Scholar
• Rufer M, Hand I, Alsleben H, Braatz A, Ortmann J, Katenkamp B, et al. Long-term course and outcome of obsessive-compulsive patients after cognitive-behavioral therapy in combination with either fluvoxamine or placebo: a 7-year follow-up of a randomized double-blind trial. Eur Arch Psychiatry Clin Neurosci 2005; 255: 121–128
   PubMed Web of Science ®Google Scholar
• RUPPASG 2001. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. New Engl J Med 344:1279–1285.
   Google Scholar
• Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2007a; 25: 182–189
   Web of Science ®Google Scholar
• Rynn M, Riddle MA, Yeung PP, Kunz NR. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007b; 164: 290–300
   PubMed Web of Science ®Google Scholar
• Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 2008; 25: 182–189
   PubMed Web of Science ®Google Scholar
• Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry 2001; 158: 2008–2014
   PubMed Web of Science ®Google Scholar
• Sachdev P, Hay P. Does neurosurgery for obsessive-compulsive disorder produce personality change?. J Nerv Ment Dis 1995; 183: 408–413
   PubMed Web of Science ®Google Scholar
• Sachdev PS, Loo CK, Mitchell PB, McFarquhar TF, Malhi GS. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol Med 2007; 37: 1645–1649
   PubMed Web of Science ®Google Scholar
• Salaberria K, Echeburua E. Long-term outcome of cognitive therapy's contribution to self-exposure in vivo to the treatment of generalized social phobia. Behav Modif 1998; 22: 262–284
   Google Scholar
• Sandmann J, Lorch B, Bandelow B, Hartter S, Winter P, Hiemke C, et al. Fluvoxamine or placebo in the treatment of panic disorder and relationship to blood concentrations of fluvoxamine. Pharmacopsychiatry 1998; 31: 117–121
   PubMed Web of Science ®Google Scholar
• Sartorius N, Üstün TB, Lecrubier Y, Wittchen HU. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996; 30: 38–43
   Google Scholar
• Sattar SP, Ucci B, Grant K, Bhatia SC, Petty F. Quetiapine therapy for posttraumatic stress disorder. Ann Pharmacother 2002; 36: 1875–1878
   PubMed Web of Science ®Google Scholar
• Saxena S, Wang D, Bystritsky A, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996; 57: 303–306
   PubMed Web of Science ®Google Scholar
• Scahill L, Hamrin V, Pachler ME. The use of selective serotonin reuptake inhibitors in children and adolescents with major depression. J Child Adolesc Psychiatr Nurs 2005; 18: 86–89
   PubMedGoogle Scholar
• Scheck M, Schaeffer JA, Gillette C. Brief psychological intervention with traumatized young women: The efficacy of eye movement desensitization and reprocessing. J Traumatic Stress 1998; 11: 25–44
   PubMed Web of Science ®Google Scholar
• Schelling G, Briegel J, Roozendaal B, Stoll C, Rothenhausler HB, Kapfhammer HP. The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry 2001; 50: 978–985
   PubMed Web of Science ®Google Scholar
• Schelling G, Roozendaal B, De Quervain DJ. Can posttraumatic stress disorder be prevented with glucocorticoids?. Ann NY Acad Sci 2004; 1032: 158–166
   PubMed Web of Science ®Google Scholar
• Schneier FR, Garfinkel R, Kennedy B, Campeas R, Fallon B, Marshall R, et al. Ondansetron in the treatment of panic disorder. Anxiety 1996; 2: 199–202
   Google Scholar
• Schneier FR, Goetz D, Campeas R, Fallon B, Marshall R, Liebowitz MR. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70–77
   PubMed Web of Science ®Google Scholar
• Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 2000; 157: 457–459
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K. Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate. J Clin Psychopharmacol 1988; 8: 303
   Google Scholar
• Schweizer E, Pohl R, Balon R, Fox I, Rickels K, Yeragani VK. Lorazepam vs. alprazolam in the treatment of panic disorder. Pharmacopsychiatry 1990a; 23: 90–93
   PubMedGoogle Scholar
• Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1990b; 47: 908–915
   PubMed Web of Science ®Google Scholar
• Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F. The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998; 28: 713–720
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein DJ. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int Clin Psychopharmacol 1999; 14: 353–356
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein MB. Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J Clin Psychiatry 2004; 65: 244–248
   PubMed Web of Science ®Google Scholar
• Seedat S, Stein DJ, Emsley RA. Open trial of citalopram in adults with post-traumatic stress disorder. Int J Neuropsychopharmacol 2000; 3: 135–140
   PubMedGoogle Scholar
• Seedat S, Lockhat R, Kaminer D, Zungu-Dirwayi N, Stein DJ. An open trial of citalopram in adolescents with post-traumatic stress disorder. Int Clin Psychopharmacol 2001; 16: 21–25
   PubMed Web of Science ®Google Scholar
• Seedat S, van Rheede van Oudtshoorn E, Muller JE, Mohr N, Stein DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol 2003; 18: 279–284
   PubMed Web of Science ®Google Scholar
• Segool NK, Carlson JS. Efficacy of cognitive-behavioral and pharmacological treatments for children with social anxiety. Depress Anxiety 2007; 25: 620–631
   Google Scholar
• Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, et al. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 2006; 26: 45–49
   PubMed Web of Science ®Google Scholar
• Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. New Engl J Med 1993; 13: 1398–1405
   Google Scholar
• Shalev AY, Bonne O, Eth S. Treatment of posttraumatic stress disorder: a review. Psychosom Med 1996; 58: 165–182
   PubMed Web of Science ®Google Scholar
• Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, et al. A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol Psychiatry 2004; 55: 553–555
   PubMed Web of Science ®Google Scholar
• Sharp DM, Power KG, Simpson RJ, Swanson V, Anstee JA. Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care. Br J Gen Pract 1997; 47: 150–155
   PubMed Web of Science ®Google Scholar
• Sharp SC, Hellings JA. Efficacy and safety of selective serotonin reuptake inhibitors in the treatment of depression in children and adolescents: practitioner review. Clin Drug Investig 2006; 26: 247–255
   PubMed Web of Science ®Google Scholar
• Shear MK, Pilkonis PA, Cloitre M, Leon AC. Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. Arch Gen Psychiatry 1994; 51: 395–401
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 1980; 37: 51–59
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Davidson J, Manschreck T, Van Wyck Fleet J. Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 1983; 3: 28–31
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Raj AB, Sheehan KH, Soto S. Is buspirone effective for panic disorder?. J Clin Psychopharmacol 1990; 10: 3–11
   PubMed Web of Science ®Google Scholar
• Sheehan DV, Raj AB, Harnett Sheehan K, Soto S, Knapp E. The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. Acta Psychiatr Scand 1993; 88: 1–11
   PubMedGoogle Scholar
• Sheehan DV, Burnham DB, Iyengar MK, Perera P. Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 2005; 66: 34–40
   PubMed Web of Science ®Google Scholar
• Shen BJ, Avivi YE, Todaro JF, Spiro A, Laurenceau JP, Ward KD, et al. Anxiety characteristics independently and prospectively predict myocardial infarction in men the unique contribution of anxiety among psychologic factors. J Am Coll Cardiol 2008; 51: 113–119
   PubMed Web of Science ®Google Scholar
• Shestatzky M, Greenberg D, Lerer B. A controlled trial of phenelzine in posttraumatic stress disorder. Psychiatry Res 1988; 24: 149–155
   PubMed Web of Science ®Google Scholar
• SIGN Scottish Intercollegiate Guidelines Network ( www.sign.ac.uk).
   Google Scholar
• Simeon JG, Ferguson HB, Knott V, Roberts N, Gauthier B, Dubois C, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry 1992; 31: 29–33
   PubMed Web of Science ®Google Scholar
• Simon GE, Savarino J, Operskalski B, Wang PS. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163: 41–47
   PubMed Web of Science ®Google Scholar
• Simon NM, Emmanuel N, Ballenger J, Worthington JJ, Kinrys G, Korbly NB, et al. Bupropion sustained release for panic disorder. Psychopharmacol Bull 2003; 37: 66–72
   PubMedGoogle Scholar
• Simon NM, Worthington JJ, Doyle AC, Hoge EA, Kinrys G, Fischmann D, et al. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 2004; 65: 1219–1222
   PubMed Web of Science ®Google Scholar
• Simon NM Connor KM Lang AJ Rauch S Krulewicz S Lebeau RT, et al 2008a. Paroxetine CR Augmentation for Posttraumatic Stress Disorder Refractory to Prolonged Exposure Therapy. J Clin Psychiatry e1–6.
   Google Scholar
• Simon NM, Connor KM, Lebeau RT, Hoge EA, Worthington JJ, Zhang W, et al. Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings. Psychopharmacology (Berl) 2008b; 197: 675–81
   PubMed Web of Science ®Google Scholar
• Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallon BA, Davies S, et al. Imipramine in the treatment of social phobia. J Clin Psychopharmacol 1998; 18: 132–135
   PubMed Web of Science ®Google Scholar
• Simpson HB, Liebowitz MR, Foa EB, Kozak MJ, Schmidt AB, Rowan V, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety 2004; 19: 225–233
   PubMed Web of Science ®Google Scholar
• Simpson K, Noble S. Fluoxetine – A review of its use in women's health. CNS Drugs 2000; 14: 301–328
   Web of Science ®Google Scholar
• Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007; 17: 79–93
   PubMed Web of Science ®Google Scholar
• Skoog G, Skoog I. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1999; 56: 121–127
   PubMed Web of Science ®Google Scholar
• Smith DE, Landry MJ. Benzodiazepine dependency discontinuation: focus on the chemical dependency detoxification setting and benzodiazepine-polydrug abuse. J Psychiatr Res 1990; 24(Suppl 2)145–156
   Google Scholar
• Smits JAJ, Powers MB, Buxkamper R, Telch MJ. The efficacy of videotape feedback for enhancing the effects of exposure-based treatment for social anxiety disorder: A controlled investigation. Behav Res Ther 2006; 44: 1773–1785
   Google Scholar
• Sousa MB, Isolan LR, Oliveira RR, Manfro GG, Cordioli AV. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 2006; 67: 1133–1139
   PubMed Web of Science ®Google Scholar
• Spence SH, Donovan C, Brechman-Toussaint M. The treatment of childhood social phobia: the effectiveness of a social skills training-based, cognitive-behavioural intervention, with and without parental involvement. J Child Psychol Psychiatry 2000; 41: 713–726
   PubMed Web of Science ®Google Scholar
• Spiegel DA. Psychological strategies for discontinuing benzodiazepine treatment. J Clin Psychopharmacol :S 1999; 19: 17–22
   PubMed Web of Science ®Google Scholar
• Spigset O, Hägg S. Excretion of psychotropic drugs into breast milk – Pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9: 111–134
   Web of Science ®Google Scholar
• Spivak B, Strous RD, Shaked G, Shabash E, Kotler M, Weizman A. Reboxetine versus fluvoxamine in the treatment of motor vehicle accident-related posttraumatic stress disorder: a double-blind, fixed-dosage, controlled trial. J Clin Psychopharmacol 2006; 26: 152–156
   Google Scholar
• Stahl MM, Lindquist M, Pettersson M, Edwards IR, Sanderson JH, Taylor NF, et al. Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system. Eur J Clin Pharmacol 1997; 53: 163–169
   PubMed Web of Science ®Google Scholar
• Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2003; 64: 1322–1327
   PubMed Web of Science ®Google Scholar
• Stanley MA, Beck JG, Novy DM, Averill PM, Swann AC, Diefenbach GJ, et al. Cognitive-behavioral treatment of late-life generalized anxiety disorder. J Consult Clin Psychol 2003; 71: 309–319
   PubMed Web of Science ®Google Scholar
• Stein DJ. Advances in the neurobiology of obsessive-compulsive disorder. Implications for conceptualizing putative obsessive-compulsive and spectrum disorders. Psychiatr Clin North Am 2000; 23: 545–562
   Google Scholar
• Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119–122
   PubMed Web of Science ®Google Scholar
• Stein DJ, Berk M, Els C, Emsley RA, Gittelson L, Wilson D, et al. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. S Afr Med J 1999; 89: 402–406
   Google Scholar
• Stein DJ, Cameron A, Amrein R, Montgomery SA. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol 2002a; 17: 161–170
   PubMed Web of Science ®Google Scholar
• Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002b; 59: 1111–1118
   PubMed Web of Science ®Google Scholar
• Stein DJ, Bandelow B, Hollander E, Nutt DJ, Okasha A, Pollack MH, et al. WCA recommendations for the long-term treatment of posttraumatic stress disorder. CNS Spectrums 2003a; 8: 31–39
   Google Scholar
• Stein DJ, Westenberg HG, Yang H, Li D, Barbato LM. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial. Int J Neuropsychopharmacol 2003b; 6: 317–323
   PubMed Web of Science ®Google Scholar
• Stein DJ, van der Kolk BA, Austin C, Fayyad R, Clary C. Efficacy of sertraline in posttraumatic stress disorder secondary to interpersonal trauma or childhood abuse. Ann Clin Psychiatry 2006; 18: 243–249
   PubMedGoogle Scholar
• Stein DJ, Ahokas A, Fabiano A. Agomelatine in generalized anxiety disorder: a randomized, placebo-controlled study (Poster). Eur Neuropsychophar17(Suppl 2007a; 4): S509
   Google Scholar
• Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007b; 23: 701–711
   PubMed Web of Science ®Google Scholar
• Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. J Am Med Assoc 1998; 280: 708–713
   PubMed Web of Science ®Google Scholar
• Stein MB, Ron Norton G, Walker JR, Chartier MJ, Graham R. Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study. Psychiatry Res 2000; 94: 191–200
   PubMed Web of Science ®Google Scholar
• Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1725–1727
   PubMed Web of Science ®Google Scholar
• Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002; 159: 1777–1779
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berlin) 2005; 177: 280–288
   PubMed Web of Science ®Google Scholar
• Stein MB, Kerridge C, Dimsdale JE, Hoyt DB. Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients. J Trauma Stress 2007; 20: 923–932
   PubMed Web of Science ®Google Scholar
• Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64: 250–258
   PubMed Web of Science ®Google Scholar
• Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al. D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22: 230–237
   PubMed Web of Science ®Google Scholar
• Storch EA, Lehmkuhl H, Geffken GR, Touchton A, Murphy TK. Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. Depress Anxiety 2008; 25: 172–174
   Web of Science ®Google Scholar
• Strand M, Hetta J, Rosen A, Sorensen S, Malmstrom R, Fabian C, et al. A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry (Suppl) 1990; 51: 40–45
   PubMedGoogle Scholar
• Sturm V, Lenartz D, Koulousakis A, Treuer H, Herholz K, Klein JC, et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat 2003; 26: 293–299
   PubMed Web of Science ®Google Scholar
• Swinson RP, Fergus KD, Cox BJ, Wickwire K. Efficacy of telephone-administered behavioral therapy for panic disorder with agoraphobia. Behav Res Ther 1995; 33: 465–469
   PubMed Web of Science ®Google Scholar
• Taylor CB, Hayward C, King R, Ehlers A, Margraf J, Maddock R, et al. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol 1990; 10: 112–118
   PubMed Web of Science ®Google Scholar
• Taylor F, Cahill L. Propranolol for reemergent posttraumatic stress disorder following an event of retraumatization: a case study. J Trauma Stress 2002; 15: 433–437
   PubMedGoogle Scholar
• Taylor F, Raskind MA. The alpha1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 82–85
   PubMed Web of Science ®Google Scholar
• Taylor S, Thordarson DS, Maxfield L, Fedoroff IC, Lovell K, Ogrodniczuk J. Comparative efficacy, speed, and adverse effects of three PTSD treatments: exposure therapy, EMDR, and relaxation training. J Consult Clin Psychol 2003; 71: 330–338
   PubMed Web of Science ®Google Scholar
• Telch M, Agras W, Taylor C, Roth W, Gallen C. Combined pharmacological and behavioral treatment for agoraphobia. Behav Res Ther 1985; 23: 325–335
   PubMed Web of Science ®Google Scholar
• Telch MJ, Lucas JA, Schmidt NB, Hanna HH, LaNae Jaimez T, Lucas RA. Group cognitive-behavioral treatment of panic disorder. Behav Res Ther 1993; 31: 279–287
   PubMed Web of Science ®Google Scholar
• Telch MJ, Schmidt NB, Jaimez TL, Jacquin KM, Harrington PJ. Impact of cognitive-behavioral treatment on quality of life in panic disorder patients. J Consult Clin Psychol 1995; 63: 823–830
   PubMedGoogle Scholar
• Tenneij NH, van Megen HJ, Denys DA, Westenberg HG. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. J Clin Psychiatry 2005; 66: 1169–1175
   PubMed Web of Science ®Google Scholar
• Tesar GE, Rosenbaum JF, Pollack MH, Otto MW, Sachs GS, Herman JB, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991; 52: 69–76
   PubMed Web of Science ®Google Scholar
• Teusch L, Bohme H, Gastpar M. The benefit of an insight-oriented and experiential approach on panic and agoraphobia symptoms. Results of a controlled comparison of client-centered therapy alone and in combination with behavioral exposure. Psychother Psychosom 1997; 66: 293–301
   PubMed Web of Science ®Google Scholar
• Teusch L, Bohme H, Finke J. Conflict-centered individual therapy or integration of psychotherapy methods. Process of change in client-centered psychotherapy with and without behavioral exposure therapy in agoraphobia with panic disorder. Nervenarzt 2001; 72: 31–39
   PubMedGoogle Scholar
• Thomsen PH. Child and adolescent obsessive-compulsive disorder treated with citalopram: findings from an open trial of 23 cases. J Child Adolesc Psychopharmacol 1997; 7: 157–166
   PubMed Web of Science ®Google Scholar
• Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry 1980; 37: 1281–1285
   PubMed Web of Science ®Google Scholar
• Tiffon L, Coplan JD, Papp LA, Gorman JM. Augmentation strategies with tricyclic or fluoxetine treatment in seven partially responsive panic disorder patients. J Clin Psychiatry 1994; 55: 66–69
   Google Scholar
• Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 1999; 249(Suppl 1)S7–10
   Google Scholar
• Todorov C, Freeston MH, Borgeat F. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible?. Can J Psychiatry 2000; 45: 257–262
   PubMedGoogle Scholar
• Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. J Clin Psychiatry 2004; 65: 922–931
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Rampey AH, Potvin JH, Jenike MA, Rush AJ, Kominguez RA, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 559–567
   PubMed Web of Science ®Google Scholar
• Tucker P, Zaninelli R, Yehuda R, Ruggiero L, Dillingham K, Pitts CD. Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001; 62: 860–868
   PubMed Web of Science ®Google Scholar
• Turner SM, Beidel DC, Jacob RG. Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 1994; 62: 350–358
   PubMed Web of Science ®Google Scholar
• Uhlenhuth EH, Matuzas W, Glass RM, Easton C. Response of panic disorder to fixed doses of alprazolam or imipramine. J Affect Disord 1989; 17: 261–270
   PubMed Web of Science ®Google Scholar
• Uhlenhuth EH, Warner TD, Matuzas W. Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. J Clin Psychopharmacol 2002; 22: 275–284
   PubMedGoogle Scholar
• Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JR. Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1464–1469
   PubMed Web of Science ®Google Scholar
• Vaiva G, Ducrocq F, Jezequel K, Averland B, Lestavel P, Brunet A, et al. Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma. Biol Psychiatry 2003; 54: 947–949
   PubMed Web of Science ®Google Scholar
• Vallejo J, Olivares J, Marcos T, Bulbena A, Menchon JM. Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry 1992; 161: 665–670
   PubMed Web of Science ®Google Scholar
• van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993; 54: 27–32
   PubMed Web of Science ®Google Scholar
• van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996; 39: 115–121
   PubMed Web of Science ®Google Scholar
• van Ameringen M, Mancini C, Farvolden P, Oakman J. The neurobiology of social phobia: From pharmacotherapy to brain imaging. Curr Psychiatry Rep 2000; 2: 358–366
   Google Scholar
• van Ameringen M, Allgulander C, Bandelow B, Greist JH, Hollander E, Montgomery SA, et al. WCA recommendations for the long-term treatment of social phobia. CNS Spectrums 2003; 8: 40–52
   PubMedGoogle Scholar
• Van Ameringen M, Mancini C, Pipe B, Oakman J, Bennett M. An open trial of topiramate in the treatment of generalized social phobia. J Clin Psychiatry 2004; 65: 1674–1678
   PubMed Web of Science ®Google Scholar
• Van Ameringen M, Mancini C, Patterson B, Bennett M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety 2006; 23: 1–5
   PubMed Web of Science ®Google Scholar
• van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001; 158: 275–281
   PubMed Web of Science ®Google Scholar
• van Balkom AJ, Bakker A, Spinhoven P, Blaauw BM, Smeenk S, Ruesink B. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997; 185: 510–516
   PubMedGoogle Scholar
• van Balkom AJ, de Haan E, van Oppen P, Spinhoven P, Hoogduin KA, van Dyck R. Cognitive and behavioral therapies alone versus in combination with fluvoxamine in the treatment of obsessive compulsive disorder. J Nerv Ment Dis 1998; 186: 492–499
   PubMed Web of Science ®Google Scholar
• van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, et al. Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55: 517–522
   PubMed Web of Science ®Google Scholar
• van der Kolk BA, Spinazzola J, Blaustein ME, Hopper JW, Hopper EK, Korn DL, et al. A randomized clinical trial of eye movement desensitization and reprocessing (EMDR), fluoxetine, and pill placebo in the treatment of posttraumatic stress disorder: treatment effects and long-term maintenance. J Clin Psychiatry 2007; 68: 37–46
   PubMed Web of Science ®Google Scholar
• van der Linden GJ, Stein DJ, van Balkom AJ. The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 2000; 15(Suppl 2)S15–23
   PubMedGoogle Scholar
• van Emmerik AA, Kamphuis JH, Hulsbosch AM, Emmelkamp PM. Single session debriefing after psychological trauma: a meta-analysis. Lancet 2002; 360: 766–771
   PubMed Web of Science ®Google Scholar
• van Oppen P, de Haan E, van Balkom AJ, Spinhoven P, Hoogduin K, van Dyck R. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav Res Ther 1995; 33: 379–390
   PubMed Web of Science ®Google Scholar
• van Oppen P, van Balkom AJ, de Haan E, van Dyck R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J Clin Psychiatry 2005; 66: 1415–1422
   PubMedGoogle Scholar
• van Vliet I, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia – a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994; 115: 128–134
   PubMed Web of Science ®Google Scholar
• van Vliet IM, den Boer JA, Westenberg HG, Pian KL. Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 1997; 58: 164–168
   PubMed Web of Science ®Google Scholar
• Vaughan K, Armstrong MS, Gold R, O'Connor N, Jenneke W, Tarrier N. A trial of eye movement desensitization compared to image habituation training and applied muscle relaxation in post-traumatic stress disorder. J Behav Ther Exp Psychiatry 1994; 25: 283–291
   PubMed Web of Science ®Google Scholar
• Versiani M, Mundim FD, Nardi AE, Liebowitz MR. Tranylcypromine in social phobia. J Clin Psychopharmacol 1988; 8: 279–283
   PubMed Web of Science ®Google Scholar
• Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353–360
   PubMed Web of Science ®Google Scholar
• Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002; 63: 31–37
   PubMed Web of Science ®Google Scholar
• Veteran Affairs . 2007. Department of Veteran Affairs: Post-Traumatic Stress Disorder. Clinical Practice Guidelines.
   Google Scholar
• Vogel PA, Gotestam G. Adding cognitive therapy elements to exposure therapy for obsessive compulsive disorder: a controlled study. Behav Cogn Psychother 2004; 32: 275–290
   Web of Science ®Google Scholar
• Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T. The effect of citalopram in panic disorder. Br J Psychiatry 1997; 170: 549–553
   PubMed Web of Science ®Google Scholar
• Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003; 13(Suppl 1)S53–60
   PubMedGoogle Scholar
• Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61: 1153–1162
   PubMed Web of Science ®Google Scholar
• Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000; 20: 636–644
   PubMed Web of Science ®Google Scholar
• Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 629–640
   PubMed Web of Science ®Google Scholar
• Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry 2001; 34: 128–131
   PubMed Web of Science ®Google Scholar
• Wedekind D Broocks A Weiss P Rotter-Glattkowski K Engel K Neubert K, et al . submitted. A randomized, controlled trial on the effects of paroxetine versus placebo in combination with aerobic exercise or relaxation training in the treatment of panic disorder.
   Google Scholar
• Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 1999; 60: 524–527
   PubMed Web of Science ®Google Scholar
• Weissman AM, Levy BT, Hartz AJ, Bentler S, Donohue M, Ellingrod VL, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. Am J Psychiatry 2004; 161: 1066–1078
   PubMed Web of Science ®Google Scholar
• Weissman MM, Klerman GL, Markowitz JS, Ouellette R. Suicidal ideation and suicide attempts in panic disorder and attacks. New Engl J Med 1989; 321: 1209–1214
   PubMed Web of Science ®Google Scholar
• Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 2001; 69: 875–899
   PubMed Web of Science ®Google Scholar
• Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 2004; 24: 49–55
   PubMed Web of Science ®Google Scholar
• Wetherell JL, Gatz M, Craske MG. Treatment of generalized anxiety disorder in older adults. J Consult Clin Psychol 2003; 71: 31–40
   PubMed Web of Science ®Google Scholar
• Whittal ML, Thordarson DS, McLean PD. Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention. Behav Res Ther 2005; 43: 1559–1576
   PubMed Web of Science ®Google Scholar
• WHO . 1991. World Health Organisation. Tenth Revision of the International Classification of Diseases, Chapter V (F): Mental and Behavioural Disorders (including disorders of psychological development) Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organisation.
   Google Scholar
• Wiborg IM, Dahl AA. Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?. Arch Gen Psychiatry 1996; 53: 689–694
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 335–341
   PubMed Web of Science ®Google Scholar
• Williams SL, Falbo J. Cognitive and performance-based treatments for panic attacks in people with varying degrees of agoraphobic disability. Behav Res Ther 1996; 34: 253–264
   PubMed Web of Science ®Google Scholar
• Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 2002; 16: 162–171
   PubMed Web of Science ®Google Scholar
• Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe – a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005; 15: 357–376
   PubMed Web of Science ®Google Scholar
• Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761(R) in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2006; 41: 472–80
   Google Scholar
• Woerdeman PA, Willems PW, Noordmans HJ, Berkelbach van der Sprenkel JW, van Rijen PC. Frameless stereotactic subcaudate tractotomy for intractable obsessive-compulsive disorder. Acta Neurochir (Wien) 2006; 148: 633–637
   PubMed Web of Science ®Google Scholar
• Woodman CL, Noyes R. Panic disorder: treatment with valproate. J Clin Psychiatry 1994; 55: 134–136
   Google Scholar
• Woods SW, Nagy LM, Koleszar AS, Krystal JH, Heninger GR, Charney DS. Controlled trial of alprazolam supplementation during imipramine treatment of panic disorder. J Clin Psychopharmacol 1992; 12: 32–38
   PubMed Web of Science ®Google Scholar
• Worthington JJ, Pollack MH, Otto MW, McLean RY, Moroz G, Rosenbaum JF. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull 1998; 34: 199–205
   PubMedGoogle Scholar
• Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53: 653–654
   PubMed Web of Science ®Google Scholar
• Yaryura-Tobias JA, Stevens KP, Perez-Rivera R, Boullosa OE, Neziroglu F. Negative outcome after neurosurgery for refractory obsessive-compulsive spectrum disorder. World J Biol Psychiatry 2000; 1: 197–203
   PubMedGoogle Scholar
• Yoshimura R, Kaneko S, Shinkai K, Nakamura J. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels. Psychiatry Clin Neurosci 2006; 60: 389–393
   PubMed Web of Science ®Google Scholar
• Zaider TI, Heimberg RG. The relationship between psychotherapy and pharmacotherapy for social anxiety disorder. Social anxiety disorder, B Bandelow, DJ Stein. Marcel Dekker, New York, NY 2004; 299–314
   Google Scholar
• Zitrin CM, Klein DF, Woerner MG. Treatment of agoraphobia with group exposure in vivo and imipramine. Arch Gen Psychiatry 1980; 37: 63–72
   PubMed Web of Science ®Google Scholar
• Zitrin CM, Klein DF, Woerner MG, Ross DC. Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 1983; 40: 125–138
   PubMed Web of Science ®Google Scholar
• Zitterl W, Meszaros K, Hornik K, Twaroch T, Dossenbach M, Zitterl-Eglseer K, et al. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Klin Wochenschr 1999; 111: 439–442
   PubMed Web of Science ®Google Scholar
• Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22: 667–687
   PubMed Web of Science ®Google Scholar
• Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169: 468–474
   PubMed Web of Science ®Google Scholar
• Zohar J, Kindler S. Serotonergic probes in obsessive compulsive disorder. Int Clin Psychopharmacol 1992; 7(Suppl 1)39–40
   Google Scholar
• Zohar J, Amital D, Miodownik C, Kotler M, Bleich A, Lane RM, et al. Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 2002; 22: 190–195
   PubMed Web of Science ®Google Scholar
• Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother 2008; 8: 339–349
   PubMedGoogle Scholar
• Zohar J, Fostick L, Sonnino R, Harari E, Sasson Y. Antipsychotics in OCD. Obsessive-compulsive disorder and comorbidity, R Gross-Isseroff, A Weizman. Nova Science Publishers, New York, NY 2006; 79–90
   Google Scholar
• Zwanzger P, Baghai T, Boerner RJ, Möller HJ, Rupprecht R. Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 2001a; 21: 539–540
   PubMedGoogle Scholar
• Zwanzger P, Baghai TC, Schule C, Minov C, Padberg F, Möller HJ, et al. Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 2001b; 62: 656–657
   PubMed Web of Science ®Google Scholar